SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions April category listing, related patent applications 04/12

20120100068 - Anti-cd74 immunoconjugates and methods of use: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and... Agent: The Ohio State University

20120100067 - Solubilisation method: The present invention relates to the solubilisation of an active agent in a lipid dispersion, in particular to the solubilisation of an active agent in a suspension of preformed empty liposomes.... Agent: Medigene Ag

20120100069 - B-lymphocyte targeting agents for use in a method for the treatment of a disease: The present invention is related to a B-lymphocyte targeting agent for use in a method for the treatment or diagnosis of cardiac insufficiency. Furthermore, it is related to a composition comprising such B-lymphocyte targeting agent and methods for determining whether a patient suffering from cardiac insufficiency is amenable to the... Agent:

20120100070 - Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells: Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide... Agent: Board Of Regents, The University Of Texas System

20120100072 - Pet imaging of fibrogenesis: The present invention relates to peptide compounds and their use for in vivo imaging using positron emission tomography (PET). More specifically, the invention relates to the use of such peptide-based compounds in a method for the in vivo imaging of liver fibrosis.... Agent: Ge Healthcare Limited

20120100071 - Synthesis and use of radiolabelled insulin analogues: A radiolabelled insulin analogue is provided. The analogue comprises a radiolabel linked to an insulin analogue at an amino acid at the terminal end of the B chain of the insulin analogue.... Agent:

20120100073 - Pet radiotracers for imaging fatty acid metabolism and storage: Fatty acid analogue (FAA) molecules comprising positron-emitting radionuclides, salts thereof, and FAA-triglycerides are disclosed. Also disclosed are methods of synthesis, and methods of imaging distribution and metabolism of fatty acids and fatty acid triglycerides.... Agent: Washington University

20120100075 - Fluorescent gold nanocluster matrix: The present invention discloses a fluorescent gold nanocluster, comprising: a dihydrolipoic acid ligand (DHLA) on the surface thereof, wherein the fluorescent gold nanocluster generates fluorescence by the interaction between the dihydrolipoic acid ligand and the nanocluster and the particle diameter of the fluorescent gold nanocluster is between 0.5 nm and... Agent: Chung Yuan Christian University

20120100074 - Humanized antibodies against light and uses thereof: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease;... Agent: Teva Biopharmaceuticals Usa, Inc.

20120100076 - Methods of modulating cold sensory perception: The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods... Agent: The Regents Of The University Of California

20120100079 - Stimuli-responsive carriers for mpi-guided drug delivery: The present invention relates to a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent; wherein said shell structure is capable of releasing its contents into the exterior upon the application of... Agent: Koninklijke Philips Electronics N.v.

20120100077 - Mixture of amphipathic molecules and method for modifying cell membranes by means of fusion: Disclosed is a mixture of amphipathic molecules and a method for modifying cells in vivo by way of membrane fusion with these molecules.... Agent: Forschungszentrum Juelich Gmbh

20120100078 - Pyrazine derivatives and uses thereof in renal monitoring: X1 to X4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y1 to Y4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal... Agent: Mallinckrodt LLC

20120100081 - Composition and method for treating wounds: Provided, among other things, is a method of treating a wound comprising: periodically applying to the wound over a course of days an effective amount of a water based formulation (comprising: 0.5 to 5 wt % of an emollient comprising silicone oil, 2 to 10 wt % of fatty acid,... Agent: Quinnova Pharmaceuticals, Inc.

20120100080 - Econazole composition and methods of treatment therewith: The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation.... Agent: Quinnova Pharmaceuticals, Inc.

20120100082 - Oral composition: Provided is an oral composition having a tongue coating removing effect and a strong bad breath removing effect. An oral composition having a tongue coating removing action, characterized by containing an extract of eucalyptus, a plant of the Myrtaceae family, as an essential ingredient.... Agent:

20120100085 - Composition containing sorbitan monocaprylate and alcohol: wherein R is a group consisting of carbon, hydrogen and optionally oxygen atoms with 5 to 12, preferably 6 to 11, carbon atoms, and the carbon atoms can be interlinked in, a linear, branched and/or cyclic fashion via saturated, unsaturated and/or aromatic carbon-carbon bonds and the groups can also contain... Agent: Clariant Finance (bvi) Limited

20120100083 - Compositions and methods for imparting a sunless tan with a vicinal diamine: A composition and method for imparting a sunless tan to skin is described. The composition and method makes use of a sunless tanning agent like dihydroxyacetone in combination with an adjuvant which is a vicinal diamine.... Agent: Conopco, Inc., D/b/a Unilever

20120100084 - Polymers based on arcrylic, methacrylic or ethacrylic amidoalkyl sulfonic acid or salts and carboxyalky acrylate, methacrylate or ethacrylate or oligomers of said carboxy compounds: Water-soluble or water-swellable polymers are described, containing a) 20.0 to 98.99 mole percent of one or more independently recurring structural units of the formula (1) and b) 1.0 to 79.99 mole percent of one or more independently recurring structural units of the formula (2), and c) 0.01 to 8.0 mole... Agent: Clariant Finance (bvi) Limited

20120100088 - Apigenin-containing composition: Provided is a composition which maintains apigenin stably. The present invention provides the composition containing apigenin at 3 ppm or more and dibutylhydroxytoluene, wherein the mass ratio of the content of apigenin relative to the content of dibutylhydroxytoluene is 1 or greater, or the pH value is less than 7.... Agent:

20120100086 - Bleaching peptide hydrolyzate proteasome activator and compositions containing same: The present invention relates to a peptidic hydrolyzate enriched in bioactive peptides, said hydrolyzate being a proteasome activator. In addition, the present invention relates to, on the one hand, a cosmetic or pharmaceutical composition comprising said hydrolyzate in a physiologically acceptable medium and, on the other hand, its use to... Agent:

20120100087 - Whitening cosmetic composition containing green tea extract: The present invention relates to a whitening cosmetic composition containing a green tea extract and, more particularly, to a whitening cosmetic composition containing a green tea extract that is prepared from green tea leaves by hot water extraction and liquid culture with Aspergillus oryzae to provide a high inhibitory effect... Agent:

20120100089 - Cosmetic composition for makeup and/or keratin material care, based on a mixture of resins mq and t-pr, and makeup method: The present invention relates to a composition that includes, in a physiologically acceptable medium: A) a siloxane resin containing at least 80 mol % of the following units: (i) (R′3SiO1/2)a and (ii) (SiO4/2)b where R′ is, independently, an alkyl grouping having 1 to 8 carbon atoms, an aryl grouping, a... Agent: L'oreal

20120100090 - Composition comprising a polar modified polymer: The invention relates to a composition comprising (1) at least one polar modified polymer, (2) at least one compound selected from a hyperbranched polyol having at least two hydroxyl groups, a sugar silicone surfactant, and a gelling agent.... Agent:

20120100092 - Antidandruff shampoo based on a gel network: Hair shampoo composition comprising: A. a cleaning phase, B. an azole antidandruff agent, C. and an aqueous conditioning gel network, the gel network comprising: (a) fatty material; (b) a gel network anionic surfactant comprising an alkyl group with from 16 to 30 carbons; (c) optionally a cationic surfactant; wherein the... Agent:

20120100091 - Hair-treatment composition and hair-treatment method using same: Provided is a hair-treatment composition containing: a first amphoteric surfactant having a structure represented by general formula (1) below; at least one type of second amphoteric surfactant selected from the group consisting of fatty acid amide propyldimethylaminoacetic acid betaines, alkyldimethylaminoacetic acid betaines, N-acylaminoethyl-N-2-hydroxyethylaminocarboxylic acid salts and N-acylaminoethyl-N-carboxymethoxyethylaminocarboxylic acid salts fatty... Agent: Hoyu Co., Ltd.

20120100093 - Medicinal package: The present invention relates to a medicinal package comprising a medicinal preparation capable of giving out smells, a packaging component and a chemical absorption-type desiccant. According to the present invention, a medicinal package wherein unpleasant smells are reduced is provided.... Agent: Takeda Pharmaceutical Company Limited

20120100094 - Compositions for stabilizing bacillus spores and methods of use thereof: The invention provides methods for providing Bacillus spores for application to agricultural soil or plant material as well as zootechnic applications for odor control in areas of high ammonia generation. The methods comprise suspending the Bacillus spores in a liquid consisting essentially of water and an organic acid, including acetic... Agent: Osprey Biotechnics, Inc.

20120100095 - Deodorant spray: A deodorant comprises triethyl citrate, zinc glycinate, and water. The deodorant has a pH of 5.5 to 6.5.... Agent:

20120100097 - Cellulose support containing d-mannose derivatives: Cellulose support containing mannose derivatives able to fix type 1 piliated bacteria, application to disinfecting wipes especially. Support intended to bind type 1 piliated bacteria comprising cellulose fibers and/or regenerated cellulose fibers onto which mannose derivative is fixed characterized in that the mannose derivative is present in the form of... Agent:

20120100096 - Conjugates pf small-interfering nucleic acids: The present invention relates to conjugates of small-interfering nucleic acids (siNA). Compositions of siNA suited for administration to a patient are described. Methods for delivering the compositions are also described.... Agent: Nektar Therapeutics

20120100098 - Solid form sodium lauryl sulfate (sls) pesticide composition: A composition and method of eliminating pests combines water and a solid form of sodium lauryl sulfate to form a pesticide composition effective to cause mortality in pests. The composition is applied to the indoor structure in an area which the pests inhabit. The sodium lauryl sulfate can be in... Agent: Ecolab Usa Inc.

20120100099 - Fusion proteins having mutated immunoglobulin hinge region: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue... Agent: Novagen Holding Corporation

20120100102 - Cancer vaccine: We disclose a vaccine comprising a pappalysin and vaccine compositions comprising a pappalysin.... Agent: Procure Therapeutics Limited

20120100101 - Ctla-4 antibody dosage escalation regimens: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.... Agent:

20120100100 - Cyclin dependent kinase inhibitors and methods of use: The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or... Agent:

20120100103 - In situ forming hydrogel and biomedical use thereof: Disclosed are in situ-forming injectable hydrogel and medical uses thereof. In the in situ-forming injectable hydrogel two or more homogeneous or heterogeneous polymers are bonded to each other by a dehydrogenation reaction between phenol or aniline moieties on adjacent polymers, wherein a polymer backbone is grafted with a phenol or... Agent:

20120100105 - Agent and method for treating refractory chronic hepatitis c: It is found that even refractory chronic hepatitis C can be treated effectively and safely by administering an effective amount of a combination of 22β-methoxyolean-12-ene-3β,24(4β)-diol with an IFN.... Agent: Meiji Seika Pharma Co., Ltd.

20120100104 - Antiviral compounds and uses thereof: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts,... Agent: Abbott Laboratories

20120100106 - Collagen-binding synthetic peptidoglycans for wound healing: Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient.... Agent: Purdue Research Foundation

20120100107 - In vivo transfer methods for wound healing: The present invention relates to an in vivo method for specific targeting and transfer of DNA into mammalian repair cells. The transferred DNA may include any DNA encoding a therapeutic protein of interest. The invention is based on the discovery that mammalian repair cells proliferate and migrate into a wound... Agent: The Regents Of The University Of Michigan

20120100117 - Method for chondrogenic differentiation of pluripotent or multipotent stem cells using wnt6: The present invention relates to methods for obtaining chondrocytes by culturing pluripotent or multipotent stem cells with a culture medium comprising Wnt6 or a derivative thereof. The inventive methods have the advantage of specifically leading to chondrogenic lineage and providing chondrocytes without differentiation towards hypertrophic chondrocytes, adipocytes or osteoblasts.... Agent:

20120100116 - Neuron generation, regeneration and protection: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said... Agent: Institut Pasteur

20120100115 - Regionalised endoderm cells and uses thereof: The present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells. The invention also relates to cell lines, cell culture methods, cells markers and the like and their potential uses in... Agent: The University Court Of The University Of Edinburgh

20120100108 - Compositions and methods of treating no-option critical limb ischemia (cli): The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using... Agent: Aastrom Biosciences, Inc.

20120100118 - Methods of treating pigs with bacillus strains: Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration... Agent: Danisco A/s

20120100119 - Hydrolysis resistant organomodified trisiloxane surfactants: are described wherein the substituents on the differing M and M′ groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household... Agent: Momentive Performance Materials Inc.

20120100109 - Method for increasing the replication of oncolytic hsvs in highly resistant tumor cells using mtor pathway and pi3k inhibitors: The present invention is directed to the administration of an HSV derived oncolytic virus and a PI3K/AKT/mTOR pathway inhibitor to treat various types of resistant tumors. Therapy-resistant tumor formation is one of the main causes for treatment failure in the clinic. The treatment methods and compositions disclosed herein sensitize resistant... Agent:

20120100113 - Differentiation method for production of glial cell populations: The present invention provides methods for generating oligodendrocyte progenitor cells from pluripotent cells, as well as methods for sustaining these oligodendrocyte progenitor cells in relatively pure cultures for long periods of time. The present invention also provides methods for further differentiating these oligodendrocyte progenitor cells into various glial cells.... Agent: Case Western Reserve University

20120100112 - Materials and methods for using adipose stem cells to treat lung injury and disease: The present invention provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or... Agent: Indiana University Research And Technology Corporation

20120100114 - Mesenchymal stem cells and supports for tissue regeneration, repair and reconstruction: Materials and methods for preparing mesenchymal stem cells are described such that the mesenchymal stem cells remain for a longer period of time than would normally be found at a site of tissue healing. The mesenchymal stem cells are pretreated to exhibit osteogenic characteristics and, when combined with extracellular matrix... Agent:

20120100111 - Method for treating cancer: The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.... Agent: Universite Paris Descartes

20120100110 - Physiological methods for isolation of high purity cell populations: The disclosure provides methods for isolating a pure or enriched population of differentiated cells derived from stem cells, comprising differentiating the population of stem cells; and migrating the differentiated cells through a porous membrane in a differentiation device to isolate the pure or enriched population of differentiated cells. The disclosure... Agent: International Stem Cell Corporation

20120100120 - Performance enhancing composition and method of delivering nutrients: An aqueous composition specifically adapted for supporting physical performance. The liquid composition comprises ribose, a saccharide such as glucose or dextrose, coenzyme Q10, ATP, caffeine, and D-pinitol in conjunction with minerals and electrolytes. The orally-consumed liquid composition may be sold in solid form, such as a powder, granulate, or tablet... Agent:

20120100121 - Pegylated l-asparaginase: Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such... Agent:

20120100122 - Combination therapy: A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.... Agent: Chemigen

20120100123 - Compositions and methods for the prevention of cardiovascular disease: The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ10,... Agent:

20120100124 - Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer: The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.... Agent: Affichem

20120100125 - Local dehydration for carpal tunnel syndrome: A procedure for treating carpal tunnel syndrome can involve delivering a dehydrating agent into and/or near the carpal tunnel. The dehydrating agent can reduce swelling of the flexor tendons and/or the carpal ligament in the region, thereby reducing pressure on the median nerve that also runs through the carpal tunnel.... Agent: Kyphon Sarl

20120100127 - Method to increase the absorption of unsaturated fatty acids by human infants: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the... Agent: Swedish Orphan Biovitrum Ab (publ)

20120100126 - Method to increase the growth velocity of human infants: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their... Agent: Swedish Orphan Biovitrum Ab (publ)

20120100128 - Methods of and compositions for inhibiting the proliferation of mammalian cells: A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem

20120100129 - N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders: A vaccine for delaying onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual comprises a therapeutically effective amount of a physiologically acceptable protofibril/oligomer comprising N-terminal truncated Aβ. An antibody for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder... Agent:

20120100131 - Method for treatment of blood tumor using anti-tim-3 antibody: Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for... Agent: Kyowa Hakko Kirin Co., Ltd

20120100130 - Novel receptor hetero-dimers/-oligomers: A hetero-dimeric or hetero-oligomeric receptor, comprising at least one chemokine receptor subunit associated with at least one angiotensin receptor subunit.... Agent: Dimerix Bioscience Pty Ltd.

20120100135 - Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer: The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with topoisomerase inhibitor therapy or anti-EGFR and topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.... Agent: University Of Southern California

20120100134 - Genetic variants in angiogenesis pathway associated with clinical outcome: The invention provides methods for determining the clinical outcomes for treatment with various treatment regimens available to cancer patients based on genotypes of the patients for genetic polymorphism markers. The invention also provides kits for making the determination.... Agent: University Of Southern California

20120100132 - Humanized anti-human tumor necrosis factor alpha monoclonal antibody and sequence thereof: An amino acid sequence of a humanized monoclonal antibody includes an amino acid sequence of a light chain variable region, which includes SEQ ID. NO.: 1; and an amino acid sequence of a heavy chain variable region, which comprises SEQ ID. NO.: 2, wherein SEQ ID. NO.: 1 and SEQ... Agent:

20120100137 - Immunoglobulins: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.... Agent: Glaxo Group Limited

20120100136 - Methods for treating or preventing ophthalmological diseases: This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof.... Agent: Ophthotech Corporation

20120100138 - The use of inhibitors of bruton's tyrosine kinase (btk): Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more... Agent: Pharmacyclics, Inc.

20120100133 - Use of anti-cd20 antibody for treating primary intraocular lymphoma: An embodiment relates to a monoclonal antibody directed against the CD20 antgen, in which the variable region of each of the light chains is coded by murine nucleic acid sequence SEQ ID NO:1, the variable region of each of the heavy chains is coded by murine nucleic acid sequence SEQ... Agent: Lfb Biotechnologies

20120100139 - Cd86 antagonist multi-target binding proteins: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific... Agent: Emergent Product Development Seattle, LLC

20120100141 - Drug fusions and conjugates: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.... Agent:

20120100140 - Stabilized fc polypeptides with reduced effector function and methods of use: A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics.... Agent: Biogen Idec Ma Inc.

20120100142 - Monoclonal antibodies to influenza h1n1 virus uses thereof: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.... Agent:

20120100144 - Biomarker and treatment for cancer: A correlation between expression of JMJD6 polypeptide and breast cancer metastasis exists accordingly the present invention relates a diagnostic, prognostic and therapeutic biomarker to distinguish between early and advanced/metastatic cancer particularly breast cancer, including compounds and methods to treat the same.... Agent: Agency For Science, Technology And Research

20120100143 - Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon: Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the... Agent:

20120100145 - Methods for treating b-cell lymphoma by administering an anti-cd20 antibody: The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating... Agent: Regeneron Pharmaceuticals, Inc.

20120100147 - Novel antibodies and their uses in therapeutic and diagnostic methods: Polyclonal and monoclonal antibodies which specifically recognize the KTPAF50 protein, and compositions comprising thereof are provided. Also provided are uses of the KTPAF50-specific antibodies, in the diagnosis and therapeutic of conditions such as cancer, autoimmune diseases, graft rejection, neurodegenerative diseases and diabetes.... Agent: Two To Biotech Ltd.

20120100146 - Nucleotide and amino acid sequences relating to respiratory diseases and obesity: This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and... Agent:

20120100148 - Anti-ferroportin 1 monoclonal antibodies and uses thereof: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin,... Agent:

20120100149 - Injectable, non-aqueous suspension with high concentration of therapeutic agent: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer... Agent: Durect Corporation

20120100150 - Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.... Agent: New York Blood Center, Inc.

20120100151 - Antibodies or fragments thereof directed against a staphylococcus aureus epitope of isaa or isab: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.... Agent: Julius-maximilians-universit&#xc4 T W&#xdc Rzburg

20120100152 - Anti-human cd52 immunoglobulins: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells... Agent: Genzyme Corporation

20120100154 - Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration: Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. Another method comprises the step of... Agent: Morehouse School Of Medicine

20120100155 - Pharmaceutical agent: Provided is a pharmaceutical agent for use in the treatment of inflammation, in a subject prone to and/or experiencing an excessive inflammatory response as a result of infection with an infectious agent and/or exposure to an allergen and/or exposure to an environmental trigger, which pharmaceutical agent comprises an agent for... Agent: Peptcell Limited

20120100153 - Stable and soluble antibodies: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in... Agent: Esbatech, An Alcon Biomedical Research Unit, LLC

20120100156 - Therapeutic agent: Anti-HLA and other antibodies are present in goat serum after injection of HIV antigenic material, and form the basis for a most surprisingly effective treatment of HIV, multiple sclerosis and other conditions.... Agent:

20120100158 - Anti ceacam1 antibodies and methods of using same: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.... Agent: Ramot At Tel Aviv University Ltd.

20120100157 - Biomarker and method for predicting sensitivity to met inhibitors: Methods for determining the responsiveness of a Met-related cancer in a subject to treatment with a Met inhibitor. Kits for performing the disclosed methods are also provided. The present invention also provides a method of treating glioblastomamultiforme (GBM) in a subject in need thereof, the method comprises administering a therapeutically... Agent: Van Andel Research Institute

20120100159 - Anti-tat226 antibodies and immunoconjugates: Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided.... Agent:

20120100160 - Methods for inducing mixed chimerism: Fusion protein-siRNA complexes that specifically target activated T cells, and methods of use thereof, are described.... Agent: The General Hospital Corporation

20120100161 - Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens.... Agent:

20120100162 - Cyclophosphamide in combination with immune therapeutics: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug, either alone, or in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific... Agent: The Johns Hopkins University

20120100164 - Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material: The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material... Agent: Alk-abello A/s

20120100163 - Suppression of a type 1 hypersensitivity immune response with an unrelated antigen: The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral... Agent: Alk-abello A/s

20120100167 - Allergen peptide fragments and use thereof for treatment of dust mite allergies: The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.... Agent: Anergis S.a.

20120100166 - Ang-2 binding complexes and uses thereof: Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.... Agent: Zyngenia, Inc.

20120100165 - Drug transporter, and adjuvant and vaccine each utilizing same: An objective of the invention is to provide a drug delivery vehicle capable of allowing a vaccine or adjuvant to reach a target cell or tissue efficiently while being capable of improving the immunogenicity of the vaccine or capable of enhancing the immunostimulating effect of the adjuvant as well as... Agent: University Of The Ryukyus

20120100168 - Cyclovirus and methods of use: Provided herein are sequences of the genomes and encoded proteins of a novel virus, termed cyclovirus, and variants thereof. Also provided are methods of detecting cyclovirus and diagnosing cyclovirus infection, methods of treating or preventing cyclovirus infection, and methods for identifying anti-cyclovirus compounds. Further provided are vaccines and methods of... Agent: Blood Systems, Inc.

20120100169 - Vaccine for cervical cancer: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically... Agent: Eyegene Inc.

20120100170 - Compositions and methods for the treatment of hepatitis c: The present invention provides compositions and methods for delivery of one or more hepatitis C virus (HCV) antigens using a bacterium recombinantly encoding and expressing such antigens. In certain embodiments, the bacterial platform comprises the use of attenuated and killed but metabolically active forms of Listeria monocytogenes.... Agent:

20120100171 - Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions: This invention relates to immunogenic compositions for inducing an immune response against an antigen of interest. In particular, the invention provides immunogenic compositions comprising an antigen-carrier conjugate, wherein the carrier is a bacterial toxin that contains a signal peptide. The invention also provides methods of generating immunogenic compositions with enhanced... Agent:

20120100172 - Immunogenic streptococcus pneumoniae peptides and peptide-multimers: The present invention relates to immunogenic peptides, including variants and analogs derived from Streptococcus pneumoniae (S. pneumoniae) proteins, to peptide-multimers, conjugates and fusion proteins that include such peptides, and to vaccines that include such immunogenic entities. In particular, the present invention relates to the use of such vaccines for eliciting... Agent:

20120100173 - Methods for preparing and using multichaperone-antigen complexes: The present invention relates to methods for preparing and using multichaperone-antigen complexes. The present invention uses HOP affinity molecules in affinity methods to isolate multichaperone (multi-HSP)-antigen complexes. Such complexes have use in therapy.... Agent: Agenus Inc.

20120100174 - Composition comprising sortase anchored surface proteins of streptococcus uberis: The present invention provides an immunogenic composition comprising one or more Streptococcus uberis sortase-anchored surface proteins, or an immunogenic part thereof, wherein the composition is capable of eliciting an immune response, when administered to a subject.... Agent: The University Of Nottingham

20120100175 - Antrocin containing pharmaceutical compositions for inhibiting cancer cells: This subject invention is directed to a method for inhibition of cancer cells, comprising administrating an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, wherein the cancer cells are selected from colorectal cancer cells, liver cancer... Agent: Chaoyang University Of Technology

20120100176 - Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens: Immunization platforms, immunization regimes and medicaments useful for inducing an immune response in a mammal and preventing or treating a pathogenic infection in a mammal, wherein said immunization platforms and medicaments comprise a recombinant vesicular stomatitis virus (VSV) of one serotype and a rVSV of another serotype and are used... Agent:

20120100177 - Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof: The present invention relates to Salmonella enterica comprising at least one pgl operon of Campylobacter jejuni or a functional derivative thereof and presenting at least one N-glycan of Campylobacter jejuni or N-glycan derivative thereof on its cell surface. In addition, it is directed to medical uses and pharmaceutical compositions thereof... Agent: Eidge-noessische Technische Hochschule Zurich

20120100178 - Compositions and methods for treatment of microbial infections: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can... Agent:

20120100180 - Methods for proliferation of antigen-specific t cells: Methods for expansion of antigen-specific T cells are provided. Said methods include following steps: generating antigen-specific T cells by stimulation of T cells with antigen A; introducing genes encoding immune recognition molecule specific to major histocompatibility complex (MHC) molecule bound with a peptide derived from antigen B into the antigen... Agent: Institute Of Microbiology,chinese Academy Of Sciences

20120100179 - Use of micrornas to control virus helper nucleic acids: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are... Agent: Alphavax, Inc.

20120100181 - Attenuation of encephalitogenic alphavirus and uses thereof: The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely,... Agent: The Board Of Regents Of The University Of Texas System

20120100187 - Coatings and methods for controlled elution of hydrophilic active agents: Embodiments of the invention include multi-layer coatings and methods for controlling the elution of hydrophilic active agents. In an embodiment, the invention includes a medical device including a substrate, a primer polymer layer disposed on the substrate, an expandable layer disposed on the primer polymer layer, and a hydrophilic active... Agent: Surmodics, Inc.

20120100182 - Continuous cell programming devices: The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.... Agent:

20120100190 - Controlled release sterile injectable aripiprazole formulation and method: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Agent: Otsuka Pharmaceutical Co., Ltd.

20120100189 - Delayed release rasagiline malate formulation: Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.... Agent: Teva Pharmaceutical Industries Ltd.

20120100192 - Local therapeutic release device: An oral delivery device for the treatment of periodontal disease, the device being in a solid unit dosage form configured for insertion into a periodontal pocket of a patient. The device consists of: (a) a biodegradable pharmaceutically acceptable water-insoluble polymer in the form of a matrix; (b) a therapeutically effective... Agent: Dexcel Pharma Technologies Ltd.

20120100191 - Methods and devices for delivery of pharmaceutical agents within orifices of the body: A device for drug delivery to an orifice of a subject, comprising a shell which is elastically stressed by an active pharmaceutical ingredient, said shell containing and being substantially impermeable to said active pharmaceutical ingredient, wherein said shell has at least one hole sized for in-vivo release of said active... Agent:

20120100186 - Nanoparticulate-based contraceptive/anti-hiv composition and methods: Nanoparticulate compositions which employ membrane-integrating peptides to effect contraception and/or protection against infection by sexually transmitted virus are described.... Agent: Washington University

20120100185 - Regeneration of tissue without cell transplantation: The present invention provides methods and compositions for tissue regeneration without cell transplantation.... Agent:

20120100188 - Solid state forms of paliperidone salts and process for the preparation thereof: Provided herein are solid state forms of paliperidone salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. Paliperidone is represented by the following structural formula (I): More particularly, provided are solid state forms of paliperidone acid addition salts, wherein the acid counter ion is provided by an acid... Agent: Actavis Group Ptc Ehf

20120100184 - Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate: (i) reacting 1-amino-1,3,3,5,5-pentamethylcyclohexane with methane sulfonic acid in a solvent or a mixture of two or more solvents selected from anisole, cumene, pentane, hexane, heptane, isooctane, methyl acetate, propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, methyl ethyl ketone, methyl isopropylketone, methyl isobutyl ketone, dimethyl sulphoxide, tetrahydrofuran, methyltetrahydrofuran, 1,1-diethoxypropane, 1,1-dimethoxymethane,... Agent: Merz Pharma Gmbh & Co.kgaa

20120100183 - Topical base and active agent-containing compositions, and methods for improving and treating skin: The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders... Agent:

20120100194 - Chewing gum composition, chewing gum product, and method for manufacturing same: The invention relates to a chewing gum composition, a chewing gum product, and a method for manufacturing the same where the chewing gum composition includes: a gum base; and a gingivitis-inhibiting amount of hyaluronic acid or a physiologically acceptable salt thereof.... Agent: Kraft Foods Global Brands LLC

20120100195 - Deodorant or antiperspirant impregnated wipes: An apparatus for facilitating the application of anti-perspirant and/or deodorant to an individual is disclosed. The apparatus comprises a planar element, which may be circular in shape and composed of an absorbent material, a first pocket disposed on a first side of the planar element, wherein the first pocket accommodates... Agent:

20120100197 - Novel esters, and use thereof: The invention relates to esters of general formula (I) R1—C(═O)—O—R2, wherein (1) R1 represents a linear alkyl radical having 7 to 9 carbon atoms and R2 represents a linear alkyl radical having 9 to 10 carbon atoms or (2) R1 is a linear alkyl radical having 8 to 9 carbon... Agent: CognisIPManagement Gmbh

20120100196 - Oily dispersion and cosmetic material incorporating this oily dispersion: An oily dispersion of an inorganic microparticle oxide powder that exhibits excellent texture has superior compatibility with other cosmetic material components. The oily dispersion contains only two components of a dispersion medium and a surface-treated inorganic microparticle oxide powder, wherein the dispersion medium is an oil, the surface-treated inorganic microparticle... Agent: Tayca Corporation

20120100193 - Oral compositions and uses thereof: The present invention is directed to oral compositions comprising an orally-acceptable carrier and a silica abrasive comprising a precipitated amorphous silica compound having an average particle size of from 5 μm to 20 μm, oil absorption of from 60 cc/100 g to 120 cc/100 g, and an Einlehner hardness of... Agent: Colgate-palmolive Company

20120100198 - Insect repellent textile materials: An insect repellent textile material comprises a textile substrate and at least one insect repellent compound disposed on at least one surface of the textile substrate. An insect repellent garment comprises a treated textile material as described above. A process for treating a textile material or garment comprises the steps... Agent:

20120100199 - Method for treating a periodontal disease: Provided is a method for treating a periodontal disease affecting a periodontal pocket of a patient. The method includes inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled... Agent: Dexcel Pharma Technologies Ltd.

20120100200 - System and method for satellite drug delivery: The present disclosure is directed to an implantable repository including a housing comprising at least one bioactive agent and at least one attachment member coupled to the housing, the at least one attachment member configured to couple the implantable repository to at least one of a medical device and a... Agent:

20120100201 - Thermally stable, high tensile strength encapsulated actives: In some embodiments there is a composition including a thermally stabilized active composition and a high molecular weight polymer. The thermally stabilized active composition is resistance to degradation at higher temperatures such as those used for conducting extrusion with high molecular weight polyvinyl acetate.... Agent:

20120100203 - Fabrication of biscrolled fiber using carbon nanotube sheet: Fabrication of yarns or other shaped articles from materials in powder form (or nanoparticles or nanofibers) using carbon nanotube/nanofiber sheet as a platform (template). This includes methods for fabricating biscrolled yarns using carbon nanotube/nanofiber sheets and biscrolled fibers fabricated thereby.... Agent: Board Of Regents, The University Of Texas System

20120100202 - Manufacturing of small film strips: The present invention relates to methods for forming films. In particular, the present invention relates to the formation of films on a substrate via the use of individual pumps to deposit individual wet film products onto a substrate.... Agent: Monosol Rx, LLC

20120100205 - Components for producing amphoteric liposomes: The invention suggests amphoteric lipids wherein one or more amphoteric groups having an isoelectric point between 4 and 9 are substituted on a membranous or membrane-forming amphiphilic substance, as well as liposomes containing such compounds.... Agent:

20120100207 - Process for producing liposomes by two-step emulsification method utilizing outer aqueous phase containing specific dispersing agent, process for producing liposome dispersion or dry powder thereof using the process for producing liposomes, and liposome d: [Problem] To provide a process for producing liposomes, a liposome dispersion or a dry powder of the dispersion by a two-step emulsification method using an additive (dispersing agent) by which a liposome dispersion and a dry powder thereof which can inhibit leakage of an encapsulated drug or the like from... Agent: Konica Minolta Holdings, Inc.

20120100206 - Targeted liposomes comprising n-containing bisphosphonates and uses thereof: The present is based on the finding that folate targeted liposomal alendronate (FT-AL-L) was significantly more potent against two tested cancer cell lines than the free alendronate (AL) or the non-targeted liposomal alendronate (AL-L), as observed by the increased cytotoxicity of the folate targeted liposomal alendronate. Thus, the present disclosure... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.

20120100204 - Tgf-beta stimulating agent compositions and combinations: Compositions and methods for preventing, inhibiting or treating a disorder associated with the loss of normal adult tissue architecture are provided.... Agent: Tcp Innovations Ltd

20120100209 - Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate... Agent: Elan Pharma International Limited

20120100208 - Stable pharmaceutical composition and methods of using same: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.... Agent: Amarin Pharma, Inc.

20120100210 - Composition for the administration of polymeric drugs: Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said... Agent: Ntnu Technology Transfer As

20120100211 - Material and process for incorporation of low dosage active pharmaceutical ingredients and use thereof: A low dose API pharmaceutical tablet having excellent content uniformity is provided. The tablet is formed by spray coating a support excipient with the API. The resulting composition is suitable for direct compression tablet formulation without the need for an additional granulation step to uniformly coat the API onto the... Agent:

20120100212 - Tablet having hollow structure: (b) a tablet obtained by a process including: (1) forming a crust comprising at least one filler selected from the group consisting of a sugar alcohol, a sugar, a cellulose derivative, and a starch on an outer surface of a core comprising a sublimation solid, to obtain a dry coated... Agent: Kyorin Pharmaceutical, Co., Ltd.

20120100213 - Pharmaceutical formulations of a substituted diaminopurine: Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.... Agent:

20120100214 - Sustained-release tablet and process for preparing the same: A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an... Agent: Galderma S.a.

20120100216 - Matrix carrier compositions, methods and uses: Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a... Agent: Oshadi Drug Administration Ltd.

20120100215 - Muller stem cells: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor... Agent: The Institute Of Ophthalmology

20120100217 - Polymeric material: Disclosed herein is a polymeric material comprising a conductive polymer substantially homogeneously distributed within a hydrogel. Also disclosed are methods for making the polymeric material and uses for the polymeric material.... Agent: Newsouth Innovations Pty Limited

20120100219 - Composition for the production of tablets, and method for the production of said composition: The present invention relates to a process for the preparation of a composition for the production of tablets and to a composition obtained thereby. This composition is a directly compressible composition which results both in improved tabletting properties and in improved tablet properties.... Agent:

20120100218 - Intralymphatic chemotherapy drug carriers: A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured... Agent:

20120100220 - Drug composition for treating tumor with polymeric micelle encapsulating anti-neoplastic: This present disclosure relates to pharmaceutical compositions for treating tumors using a polymeric micelle encapsulating an anti-tumor drug. The polymeric micelle comprises block copolymers comprising at least one hydrophilic block, at least one hydrophobic block, and at least one zwitterion. The present disclosure also relates to methods of enhancing the... Agent: Industrial Technology Research Institute

20120100221 - Pharmaceutical compositions containing a combination of an antihistamine and a decongestant: This invention relates to a layered pharmaceutical composition comprising a combination of an antihistamine and a decongestant.... Agent: Ranbaxy Laboratories Limited

20120100224 - Compositions against rotavirus infection and processes for producing the same: The present inventors discovered that microfiltration retentates of whey, and products obtained by treating whey using centrifugation and/or ammonium sulfate precipitation, have the activity of inhibiting rotavirus infection.... Agent:

20120100223 - Lipid-containing compositions and methods of use thereof: Lipid compositions comprising nuts, seeds, oils, legumes, fruits, grains, and dairy useful in specified amounts as dietary supplements and diet plans designed around and including the aforementioned for the prophylaxis and treatment of numerous diseases are disclosed. The compositions include omega-6 and omega-3 fatty acids where the ratio of the... Agent: Asha Nutrition Sciences, Inc.

20120100222 - Skin function-improving composition: A skin function-improving composition for oral ingestion, which contains a milk-fat globule membrane. The composition is inexpensive, is highly safe, can be ingested orally, and has an activity of improving the dry condition of the skin so as to moisturize the skin. In particular, the milk-fat globule membrane is obtained... Agent: Yotsuba Milk Products Co., Ltd.,

20120100225 - Osteoinductive bone graft injectable cement: Osteoconductive bone graft materials are provided. These compositions contain injectable cements and demineralized bone matrix fibers. The combination of these materials enables the filling of a bone void while balancing strength and resorption.... Agent: Warsaw Orthopedic, Inc.

20120100226 - Preventive remedial therapeutic agent for phosphorus impairment, oral agent for adsorbing phosphate ion contained in food, beverage and chemical, and process for producing them: The present invention provides agents for preventing, improving or treating phosphorus-related disorders and oral preparations; agents high in biosafety and phosphorus adsorptive power, which contain, as an active ingredient, ferric hydroxide as produced under such conditions that a ferrous species is present.... Agent: J-pharma Co., Ltd.

20120100227 - Kinase protein binding inhibitors: The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer.... Agent: University Of Florida Research Foundation

20120100228 - Chromium complexes as enhancers of brain glucose transporters: The embodiments disclosed herein relate to compositions for enhancing brain glucose transporters, such as GLUT1 and GLUT3, and methods of treating and/or preventing diseases or disorders associated with the regulation GLUT1 and GLUT3. Also provided are compositions that include chromium and an agent that targets the brain or the central... Agent:

20120100229 - Treatment and prevention of white matter injury with katp channel activators: The present invention includes a method of treating or preventing a CNS white matter injury in a patient in need thereof. The invention also includes a method of stimulating proliferation of a CNS cell in a patient in need thereof.... Agent: Yale University

20120100230 - Systems, devices, and/or methods for managing crops: Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, applying a treatment composition comprising or derived from a molecular matrix-residing... Agent: Dharma Ip, LLC

20120100231 - Antimicrobial compositions and methods of making and using the same: Antimicrobial (e.g., moldicide, fungicide, bacteriacide, and virucide) compositions are disclosed. Methods of making and using antimicrobial (e.g., moldicide, fungicide, bacteriacide, and virucide) compositions are also disclosed.... Agent:

20120100232 - Process for removing pesticides from ginkgo biloba extracts, and extracts obtainable by said process: t

20120100233 - Compositions for treatment and prevention of diabetic complications using osteomeles schwerinae: The present invention relates to a treatment agent for diabetic complications, and a method for the treatment of diabetic complications using the same. The present invention confirmed that Osteomeles schwerinae extract and its fractions inhibited the generation of AGEs, the index for diabetic complications, inhibited the activation of aldose reductase,... Agent: Korea Institute Of Oriental Medicine

20120100234 - Non-occluding nasal moisturizer and methods of use: Compositions are provided that provide improved nasal moisture, clarity, and lubrication. Compositions are oil-in-glycerin emulsions that include a surfactant promoting emulsification of a hydrophobic or otherwise water insoluble bioactive agent. The compositions are used in methods of promoting improved nasal moisture and reduction in nasal congestion.... Agent:

20120100235 - Papaya puree and uses thereof: The invention relates to methods of prophylactic and/or therapeutic uses of a puree preparation from Carica papaya fruit, said puree prepared by a method comprising cooking the fruit for at least 30 minutes at normal pressure, optionally in an aqueous solution which is at least twice the volume of the... Agent: Ji Kwang Inc.

20120100236 - Chromobacterium bioactive compositions and metabolites: Provided are bioactive compounds and metabolites derived from Chromobacterium species culture responsible for controlling pests, compositions containing these compounds, methods for obtaining these compounds and methods of using these compounds and compositions for controlling pests.... Agent: Marrone Bio Innovations, Inc.

20120093717 - Microsphere/nanofiber composites for delivery of drugs, growth factors, and other agents: Provided are compositions that include polymeric fibers and microspheres entrapped within the fibers, the compositions being capable of controlled delivery of one or more agents while also maintaining their structural properties. Also provided are related methods of fabricating these compositions and methods of utilizing the compositions to deliver agents to... Agent: The Trustees Of The University Of Pennsylvania

20120093716 - Use of antisecretory factors (af) for optimizing cellular uptake: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or... Agent: Lantmannen As-faktor Ab

20120093718 - Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery: Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject.... Agent: Wayne State University

20120093719 - Antibodies against prostate specific membrane antigen: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.... Agent: Proscan Rx Pharma Inc.

20120093720 - Molecularly imprinted polymers for use as imaging and therapeutics agents: The invention described herein provides biocompatible molecularly imprinted polymers (MIPs) that are non-toxic, water soluble, small molecular weight, and degradable in a living body. The MIPs are capable of binding to all or a portion of a specific target macromolecule associated with a disease located within the living body and... Agent:

20120093724 - Methods and compositions for the detection of cancer: Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific antigen (PSA), prostate specific membrane antigen (PSMA) or human glandular kallikrein (hK2). Various further embodiments relate more specifically to PSMA-specific peptide prodrugs that become activated to yield therapeutic drugs.... Agent: The Johns Hopkins University

20120093723 - Nanocarrier compositions and methods: This invention provides multimeric nanocarrier for in vivo delivery of a bioactive agent, comprising at least two peptide monomers reversibly or irreversibly linked with one or more of said bioactive agents, wherein said two or more of said peptide monomers are covalently linked by a biodegradable difunctional moiety, as well... Agent: Rutgers, The State University Of New Jersey

20120093722 - Synthetic diblock copolypeptide hydrogels for use in the central nervous system: This invention relates, e.g., to a composition suitable for administration to the central nervous system (CNS), comprising a block copolypeptide hydrogel, which comprises a biologically active material that is mixed with the hydrogel or that is attached to the polypeptide chain of the hydrogel, wherein the composition is suitable for... Agent: The Regents Of The University Of California

20120093721 - Uses of cancer-targeting peptides in cancer diagnosis: Cancer-targeting peptides and uses thereof in cancer diagnosis.... Agent: Academia Sinica

20120093725 - Fucoidans as ligands for the diagnosis of degenerative pathologies: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale

20120093727 - Compositions and methods for in vivo imaging of myelin in the peripheral nervous system: A method of detecting and/or labeling myelin in an animal's peripheral nervous system tissue includes administering to the animal a fluorescent stilbenzene derivative and visualizing the animal's peripheral nervous system tissue using an in vivo imaging modality.... Agent:

20120093726 - Radiolabeled fluorine derivatives of methionine: The invention provides compound which is an 18F-radiolabelled S-propylhomocysteine or a derivative thereof. The compound has an enantiomeric purity of at least about 90%. 18F-radiolabelled S-propylhomocysteine may be made by treating an N-protected ester of a substituted S-propylhomocysteine with a complexed F″ salt in the presence of a base to... Agent:

20120093728 - Mitochondrial inhibitors to treat human disease: The present invention relates to inhibitors of mitochondria-associated, granulocyte-macrophage colony stimulating factor signaling molecule (Magmas), and related compositions and uses thereof.... Agent:

20120093729 - Novel phosphorus-containing prodrugs: e

20120093730 - Molecular death tags and methods of their use: In one embodiment, a death tag for targeting a cell death marker is provided, the death tag comprising a death marker binding domain; a reporter binding domain (RBD); and a reporter component that is associated with the reporter binding domain. In another embodiment, a method of determining the efficacy of... Agent:

20120093733 - Multidomain biotags for cancer detection, diagnosis and therapy and methods of their use: In one embodiment, a biotag for targeting a cancer biomarker is provided. The biotag may include a cancer biomarker binding domain, an internalization domain, an endosomal escape domain, a lysosomal escape domain, a reporter binding domain, and a reporter, wherein the reporter is a diagnostic agent. In some aspects, the... Agent:

20120093734 - Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma: Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma are disclosed. A method for identifying cell-surface proteins, which are transmembrane proteins or proteins with a signal peptide and which are over-expressed in colorectal cancer (CRC) is disclosed. Biomarkers found with this method, diagnostic methods using them and contrast agents... Agent: Vereniging Voor Christelijk Hoger Onderwijs, Wettenschappelijk Onderzoek En Patientenzorg

20120093735 - Complex compound and mri probe made of same: Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose... Agent:

20120093731 - Gas-filled microvesicles with targeting ligand or therapeutic agent: Gas-filled microvesicles comprising a boundary envelope containing a gas, wherein said microvesicles comprise: —a first component, bound to said envelope, having binding affinity for an Fc-region of an antibody; and—a second component comprising a Fc-region of an antibody, bound to said first component through said Fc-region, said second component comprising... Agent: Bracco Research S.a.

20120093732 - Ultrasound contrast agents and methods of making and using them: The invention is directed to injectable suspensions of gas-filled microvesicles, as well as methods of preparing and using the same, especially as ultrasound contrast agents.... Agent: Bracco Suisse S.a.

20120093736 - Reversible color-changing ink formulations and nonwoven wipes: A reversible color-changing ink formulation, and a nonwoven wipe to which the ink formulation is securely bound, are provided. The reversible color-changing ink formulation includes about 55-98% by weight of a polymer binder, about 0.1-20% by weight of a reversible color-changing dye that reversibly changes between a first color and... Agent: Illinois Tool Works Inc.

20120093737 - Light-absorbing compositions and methods of use: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.... Agent:

20120093738 - Taste-masked oral formulations of influenza antivirals: The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the... Agent: Rubicon Research Private Limited

20120093739 - Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore: The invention relates to formulations useful in treating hair disorders, improving the health of hair, increasing hair growth, and in increasing the niacin content of hair follicles. Nicotinic acid alkyl esters having a straight chain alkyl group of from 1 to 22 methylene units, preferably from 6 to 16 methylene... Agent:

20120093740 - Peptide fragments for inducing synthesis of extracellular matrix proteins: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid,... Agent: Helix Biomedix, Inc.

20120093742 - Compounds: o

20120093741 - Dental masking compound: A photopolymerizable dental composition for application to and for the isolation and protection of gums and/or teeth during dental treatment is described. The composition can include (a) one or more photopolymerizable monomers selected from the group consisting of acrylates and methacrylates, (b) one or more photoinitiators, preferably selected from the... Agent: Voco Gmbh

20120093743 - Addition of fluoride to beverages: A system and method for preventing tooth decay comprises steps or acts of adding a small dose of fluoride to a carbonated or sugar-containing beverage to prevent tooth decay by its being drunk by a user.... Agent:

20120093746 - Amino acid-modified organopolysiloxane, making method, and cosmetics: An amino acid-modified organopolysiloxane can be prepared under mild reaction conditions by reacting an amino-modified organopolysiloxane with an amino acid or amino acid derivative ester in the presence of an organometallic catalyst. The amino acid-modified organopolysiloxane having a hydrophilic group is useful in cosmetics, powder surface treatment, fiber or fabric... Agent: Shin-etsu Chemical Co., Ltd.

20120093744 - Modified oils and multiple emulsions: According to one aspect, the present invention relates to the use of a perfluoropolyether phosphate (PFPE phosphate), dissolved in water, for the preparation of oil-in-water emuisions (O/W) with high internal phase (HIPE). The internal phase (O) typically comprises at least 74% by volume of the emulsion and includes one or... Agent:

20120093745 - Peptidic hydrolyzate proteasome activators and compositions containing same: The present invention concerns a peptidic hydrolyzate enriched in bioactive peptides, said hydrolyzate being a proteasome activator. Further, the present invention concerns a cosmetic or pharmaceutical composition comprising said hydrolyzate in a physiologically acceptable medium and also its use in preventing or treating the signs of aging or photo-aging in... Agent:

20120093747 - Sunscreen cosmetic composition containing ultraviolet absorber: A sunscreen cosmetic composition contains an ultraviolet absorber composed of a triazine compound (a) represented by the general formula (1) below and a triazine compound (b) represented by chemical formula (2) below. In the general formula (I) below, R1 represents a linear or branched C1-12 alkyl group, a C3-8 cycloalkyl... Agent: Adeka Corporation

20120093750 - Cosmetic composition made from ion-exchange resins filled with lipoaminoacids: Disclosed is a composition of ion-exchange resins made from a styrene-divinylbenzene copolymer or an acrylic-divinylbenzene copolymer filled with at least one lipoaminoacid with the formula (I), in which R1 is the chain characterising a fatty acid, saturated or unsaturated, linear or branching, including 7 to 21 atoms of carbon, R2... Agent:

20120093748 - Topical personal care and pharmaceutical compositions and uses thereof: Topical compositions are provided that have 0.5% or more of at least one personal care or pharmaceutical acid, and lightly- to moderately-crosslinked PVP, which is an effective thickener in the low pH systems. In preferred embodiments, the acid is a hydroxy acid and the composition used for personal care, or... Agent: Isp Investments Inc.

20120093749 - Use of delta-tocopheryl-carbohydrate as a depigmenting agent: The present invention relates to a cosmetic or pharmaceutical composition for cutaneous application, whose goal is the depigmentation of the skin.... Agent: Pierre Fabre Dermo-cosmetique

20120093753 - Cationic polyglyceryl compositions and compounds: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently... Agent:

20120093751 - Hair cosmetic: o

20120093752 - Use of monoamine oxidase inhibitors to improve epithelial biology: The invention provides a method for improving hair biology, e.g., hair growth. The method comprises administering to a subject a monoamine oxidase inhibitor and a vasodilator, a zinc salt of a carboxylic acid, a xanthine compound, pyrithione or a salt thereof, saponin, tritapene, crataegolic acid, celastrol, asiatic acid, an inhibitor... Agent:

20120093755 - Compositions and methods for treating keratin based fibers: Compositions, formulations, kits and methods for temporarily or semi-permanently transforming the shape of individual hair filaments or keratinous fibers (curling, waving or straightening) by applying no heat or heat below about 300° F. to prevent damage to the keratinous fibers.... Agent: Maneworx Inc.

20120093756 - Concentrated shampoo: Concentrated shampoo composition comprising from 27 to 70% wt. cleansing surfactant, a conditioning gel phase, a short chain diol and an oil, wherein the conditioning gel phase comprises: (a) fatty material; (b) a gel network anionic surfactant comprising an alkyl group with from 16 to 30 carbons; (c) cationic surfactant;... Agent:

20120093757 - Composition: Hair conditioner comprising silicone and a conditioning gel phase, said phase obtainable by heating a fatty alcohol and an oil until they are molten, separately heating a cationic surfactant in water until it is dissolved/suspended, then adding the molten fatty alcohol and oil mix to the cationic surfactant before adding... Agent:

20120093758 - Hair cosmetic: The present invention provides a hair cosmetic composition contains (A) a di-long-chain cationic surfactant represented by formula (1); (B) an ethylene oxide adduct of 1,2-alkanediol represented by formula (2), and/or an N-acyl-N-methylmonoethanolamide represented by formula (3); and (C) water, wherein the number (α1) of the carbon atoms that form RaCO... Agent: Shiseido Company, Ltd.

20120093754 - Conditioning composition for keratin fibres: The present invention relates to a conditioning composition for keratin fibres especially human hair comprising particular cationic cellulose polymer and a cationic or cationizable silicone compound.... Agent: Kpss-kao Professional Salon Service Gmbh

20120093760 - Polyquaternium-1 synthesis methods: The present embodiments relate to a novel method of making quaternary ammonium polymers comprising the steps of: a) mixing 1,4-bis-dimethylamino-2-butene, triethanolamine, water and an acid; and b) introducing a 1,4-dihalo-2-butene to the mixture so as to initiate a reaction resulting in the quaternary ammonium polymer.... Agent: Abbott Medical Optics Inc.

20120093759 - Medical devices, wound dressings, and methods for dressing wounds: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.... Agent:

20120093762 - Nucleic acid delivery compounds: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.... Agent: Nitto Denko Corporation

20120093761 - Vaccine compositions and methods of use thereof: Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells).... Agent: University Of Miami

20120093763 - Rna virus infection inhibitor, method for inhibition of infection by rna virus, rna virus infection-inhibiting product, and use as rna virus infection inhibitor: Disclosed herein is an RNA virus infection inhibitor that is capable of effectively inhibiting humans from being infected with RNA viruses to prevent the occurrence of symptoms or, even when symptoms occur, to relieve the symptoms and is less likely to cause unexpected discoloration or discoloration under normal service conditions.... Agent:

20120093765 - Process for purification of recombinant human granulocyte colony stimulating factor: The present invention describes a novel process for large-scale purification of therapeutic grade quality of recombinant human GCSF from microbial cells, wherein the protein is expressed as inclusion bodies. The Inclusion bodies are solubilized and refolded under redox condition. The Redox condition is provided by using ascorbic acid, dehydroascorbic acid... Agent: Lupin Limited

20120093764 - Treatment of diabetes using g-csf and hyperbaric oxygen: A method of treating endothelial cells comprising: inducing vasodilation in a patient; and administering a composition including a stem cell proliferation agent to the patient.... Agent:

20120093768 - Anti-connexin compounds targeted to connexins and methods of use thereof: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell... Agent:

20120093766 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20120093767 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20120093770 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties... Agent:

20120093769 - Stem cell targeting with dock-and-lock (dnl) complexes: Disclosed herein are compositions and methods of use of dock and lock (DNL) complexes comprising a first antibody or fragment that binds to a stem cell antigen and a second antibody or fragment thereof that binds to an antigen on a diseased or damaged tissue or organ. The DNL complexes... Agent: Ibc Pharmaceuticals, Inc.

20120093771 - Method for preparing a hardened calcium sulfate dihydrate block and use thereof: The present invention provides a technique for prolonging the working time and setting time of a calcium sulfate hemihydrate paste by mixing calcium sulfate hemihydrate powder with an aqueous solution containing phosphate ions, so that the paste is suitable for operation and the resultant hardened calcium sulfate dihydrate block from... Agent: National Cheng Kung University

20120093774 - Auxotrophic recombinant bcg strain pasteur and use thereof in the control of human infections caused by parasites: The present invention relates to a vaccinal strain of recombinant BCG Mycobacterium bovis expressing the Schistossoma mansoni Sm14 protein (BCG Pasteur ΔleuD/pΔK410-hsp60*-Sm14). The vaccinal strain of the present invention is employed in the control of infections caused by parasites, specially the Schistossoma mansoni. The vaccinal strain is a an auxotrophic... Agent: Funda&#xc7 &#xc3 O Oswaldo Cruz

20120093777 - Compositions comprising viruses and methods for concentrating virus preparations: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.... Agent:

20120093773 - Compositions for bacterial mediated gene silencing and methods of using same: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer of cell proliferative disorders. The bacterium... Agent:

20120093775 - Methods and compositions for the treatment of cirrhosis and liver fibrosis: The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation... Agent: Proyecto De Biomedicina Cima, S.l.

20120093776 - Methods for treating diseases using a bone morphogenetic protein: Described herein are methods, uses, and pharmaceutical compositions for treating heart disease that include a bone morphogenetic protein (BMP). In addition, described herein are methods, uses, and compositions for preventing or slowing fibrosis in diseased or injured tissue, and/or for preventing or slowing cell death in diseased or injured tissue.... Agent: Indiana University Research And Technology Corporation

20120093778 - Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use: A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.... Agent: The Trustees Of The University Of Pennsylvania

20120093772 - Vectors for delivery of light sensitive proteins and methods of use: Provided herein are compositions and methods for gene and etiology-nonspecific and circuit-specific treatment of diseases, utilizing vectors for delivery of light-sensitive proteins to diseased and normal cells and tissues of interest.... Agent:

20120093790 - Hla homozygous cells and methods of use thereof: The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells.... Agent: University Of Washington

20120093785 - Human artificial chromosome (hac) vector: The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present... Agent: Kirin Beer Kabushiki Kaisha

20120093787 - Methods and compositions for inhibiting viral entry into cells: Disclosed herein are methods and compositions for inhibiting viral entry into cells.... Agent: Sangamo Biosciences, Inc.

20120093789 - Methods of modulating smooth muscle cell proliferation and differentiation: The present disclosure provides methods of inducing smooth muscle cell differentiation. The present disclosure provides genetically modified cells comprising exogenous miR-143 and/or miR-145 nucleic acids; and artificial tissues comprising the genetically modified cells. The present disclosure provides methods and compositions for reducing pathological angiogenesis. The present disclosure provides methods of... Agent:

20120093788 - Protease for wound conditioning and skin care: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is... Agent: B.r.a.i.n. Biotechnology Research And Information Network Ag

20120093786 - Treatment of limb ischemia: The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease.... Agent: Reneuron Limited

20120093779 - Complex microbial preparation for treating diabetes and preparative method and use thereof: A complex microbial preparation comprises (in vol. %): Photosynthetic bacterium (5-15%), Bacillus (10-20%), Yeasts (20-35%), Lactobacillus (30-45%) and Actinomycetes (3-10%). The preparative method of the complex microbial preparation involves first and second level complex fermentations. The first level complex fermentation involves: (a) separately inoculating the above-mentioned bacteria on first level... Agent:

20120093791 - Stimulation of innate immunity with an antigen from bacterial origin: There is provided a method of attenuating a respiratory infection in a subject, use of a composition for the manufacture of a medicament and a composition for treating respiratory infections comprising a preparation of Saccharopolyspora rectivirgula (SR), a non pathogenic thermophilic actinomycetes, which can stimulate the innate pulmonary immune response.... Agent:

20120093780 - Process for producing poxviruses and poxvirus compositions: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation... Agent: Transgene S.a.

20120093784 - Compositions and methods for controlling stem cell and tumor cell differentiation, growth, and formation: The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.... Agent: Northwestern University

20120093782 - Enhanced hematopoietic stem cell engraftment: The invention relates to improved products, processes, and therapeutic methods relating to hematopoietic stem cells and hematopoietic stem cell transplantation. Included are methods for improving transplant efficiency of cord blood units comprising use of mixtures of expanded CD34+/CD 133− HSCs and unexpanded CD133+ HSCs for IBM administration.... Agent:

20120093781 - Human mast cell line and uses thereof: The subject invention pertains to the development of a novel human mast cell line, USF-MC1. USF-MC1 is a mast cell precursor present in human umbilical cord blood (HUCB) that may be sustained in culture in the absence of exogenous cytokines to serve as a convenient experimental model of human mast... Agent: University Of South Florida

20120093783 - Use adipose tissue-derived regenerative cells in the modulation of inflammation in the pancreas and in the kidney: Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating inflammation.... Agent: Cytori Therapeutics, Inc.

20120093792 - Immunotherapy for pancreatic cancer: The present invention provides an immunotherapeutic agent and immunotherapy allowing the extension of the survival time of patients with pancreatic cancer. The immunotherapy of the present invention is characterized by comprising the steps of culturing peripheral blood lymphocytes of a patient with pancreatic cancer by stimulating the lymphocytes with an... Agent:

20120093793 - Methods of preventing platelet alloimmunization and alloimmune platelet refractoriness and induction of tolerance in transfused recipients: Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.... Agent:

20120093795 - Compounds targeting the cation-independent mannose 6-phosphate receptor: The invention relates to conjugates of products of interest and of compounds targeting the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies.... Agent: Centre National De La Recherche Scientifique-cnrs

20120093794 - Methods for treating pompe disease: The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor... Agent: Biomarin Pharmaceutical Inc.

20120093796 - Novel use of ec-sod and method for preparing thereof: The present invention relates to compositions for preventing or treating angiogenesis-mediated diseases or allergic diseases which contain, as an active ingredient, an EC-SOD protein or a vector having a polynucleotide encoding thereof. The EC-SOD protein or the vector having a polynucleotide encoding the EC-SOD protein has the effect on inhibiting... Agent: Industry Academic Cooperation Foundation, The Catholic University Of Korea

20120093797 - Combined use of creatine phosphate and creatine phosphokinase for treatment of arteriosclerosis: Disclosed are a creatine phosphate (CP) and creatine phosphokinase (CPK) in association for use in the treatment of an atherosclerotic plaque present in the wall of an artery of a patient.... Agent: Artcell Invest Ltd.

20120093798 - Methods for treatment of stroke or cerebrovascular: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.... Agent: Midwestern University

20120093799 - Recombinantly modified plasmin: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the... Agent:

20120093800 - plant extract comprising statins and preparation techniques and uses thereof: A plant extract comprising one or more statins and being substantially free of polar compounds that affect pharmacokinetics of a drug in a subject is provided. Also provided is a method of preparing an extract comprising the step of removing polar compounds that affect pharmacokinetics of a drug in a... Agent: Nanyang Polytechnic

20120093802 - Bioactive composition including stabilized protein and process for producing the same: A bioactive composition includes a porous hydrogel matrix. At least one protein is immobilized in the porous hydrogel matrix forming a hydrogel protein composite that is stable in an organic solvent. A process for stabilizing a bioactive composition includes the steps of: forming hydrogel matrix pores around protein molecules and... Agent: Toyota Motor Engineering & Manufacturing North America, Inc.

20120093804 - Concatamers for immunemodulation: The invention relates to a polymeric, non-coding nucleic acid molecule for modulation of the activity of the human and animal immune system as well as a method for the manufacture thereof and a vaccine, comprising the polymeric, non-coding nucleic acid molecule, wherein polymeric, non-coding nucleic acid molecules may be understood... Agent: Mologen Ag

20120093803 - Means and methods of sterilization of biofunctional compositions: The present invention, inter alia, relates to a closed sterilized container comprising at least one carrier which is a stabilizer; and at least one biomolecule reversibly attached to the carrier, wherein said carrier partially or completely covers the attached biomolecules and wherein said at least one carrier is selected from... Agent: Leukocare Ag

20120093801 - Targeted delivery of therapeutic agents with lyophilized matrices: Embodiments of surgical grafts, and methods, for the delivery of therapeutic agents to a target tissue via acellular matrices, are described. In some embodiments, nonviable matrices are successful in preventing or lessening adhesion formation by guiding tissue repair and remodeling, while also providing the target tissue with therapeutic agents that... Agent: Telefonakiebolaget L M Ericsson (publ)

20120093813 - Anti notch-1 antibodies: This invention is directed toward monoclonal antibodies that bind specifically to Notch1. In one embodiment, the antibodies binds to at least a first epitope and a second epitope, wherein the first epitope resides with the LinA domain of the Notch1 negative regulatory region (NRR), and the second epitope resides within... Agent: Pfizer Inc

20120093805 - Anti-cd27 humanized monoclonal antibody: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically... Agent: Kyowa Hakko Kirin Co., Ltd

20120093811 - Anti-vegf-d antibodies: The invention relates to an isolated antibody that specifically binds vascular endothelial growth factor-D (VEGF-D) and to a humanized antibody that specifically binds VEGF-D.... Agent:

20120093806 - Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine: Pharmaceutical composition comprising an antibody specifically recognizing CD38 and cytarabine.... Agent: Sanofi-aventis

20120093808 - Humanized pcrv antibody having anti-pseudomonal activity: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity... Agent: Shionogi & Co., Ltd.

20120093812 - Method of treating degenerative disorders of the nervous system: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.... Agent: The Regents Of The University Of California

20120093810 - Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof: The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody... Agent: Evec Incorporated

20120093807 - Ror alpha promoting the induction of bmall: An object of the present invention is to clarify unelucidated aspects in the control mechanism of circadian rhythms. The present inventors have newly found that RORα (retinoic acid binding-receptor alpha; the same shall apply hereinafter) stimulates an induction of Bmal1 expression and also that the induction of Bmal1 expression is... Agent: Sony Corporation

20120093809 - Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms: The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound;... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20120093815 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20120093814 - Fusion proteins comprising canine fc portions: The present invention relates to therapeutic peptides and proteins fused to a canine antibody Fc domain. Methods and compositions of using the same are described.... Agent: Boehringer Ingelheim International Gmbh

20120093816 - Use of tnf-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors.... Agent: Sciaticon Ab

20120093819 - Antibodies that specifically block the biological activity of a tumor antigen: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and... Agent: Alethia Biotherapeutics Inc.

20120093818 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent:

20120093822 - Dopamine d2 receptor-disc1 interaction, compositions and methods for modulating same: The present invention provides compounds, compositions and methods for inhibiting D2R-DISC1 interaction. Specifically, the present invention provides a polypeptide comprising the amino acid sequence KIYIVLRRRRKRVNT (SEQ ID NO: 1) or SEQ ID NO:5, a fragment thereof, or a polypeptide comprising an amino acid sequence that is at least 80% identical... Agent: Centre Forr Addiction And Mental Health

20120093823 - Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used... Agent:

20120093824 - Methods for treating pruritus by administering an antibody that specifically binds human par2: The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an... Agent: Regeneron Pharmaceuticals, Inc.

20120093821 - Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are... Agent: The John Hopkins University

20120093820 - Prostatitis-associated antigens and methods of use thereof: The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further... Agent:

20120093817 - Use of the genes in the hog, ras and camp pathway for treatment of fungal infection: Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of Cryptococcus neoformans, roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when... Agent:

20120093825 - Method for producing antibody using \"naked\" expression vector expressing type ii transmembrane fusion protein: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein... Agent: Delphi Genetics Sa

20120093826 - Fully human antibodies specific to cadm1: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for... Agent: Medarex, Inc.

20120093827 - Treatment of autoimmune disorders with a neurotoxin: Methods of treating one or more autoimmune disorders include a step of administering a Clostridial neurotoxin, such as a botulinum toxin, to a patient that has an autoimmune disorder. In one aspect, a method includes a step of administering the neurotoxin to the thymus gland or near the thymus gland... Agent: Allergan, Inc.

20120093829 - New methods for treatment of inflammatory diseases: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory... Agent:

20120093828 - Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary... Agent:

20120093833 - Human oncostatin m antibodies and methods of use: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.... Agent:

20120093831 - Methods and materials for modulating resistance to apoptosis: This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of... Agent:

20120093832 - Promotion of neuronal integration in neural stem cell grafts: The invention relates to the treatment of diseases or disorders of the nervous system. In particular, the invention relates to the treatment of diseases or disorders of the nervous system by stem cell therapy, in particular therapy with neural precursor cells. In preferred aspects of the invention, inhibitors of chemoattraction... Agent: Life & Brain Gmbh

20120093830 - Single domain antibodies that bind il-13: Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.... Agent:

20120093834 - Neutralizing molecules to viral antigens: The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example... Agent:

20120093835 - Anti-inflammatory antibodies and uses therefor: The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders.... Agent:

20120093836 - Pharmaceutical compositions for treating metastasis: The present invention relates to the use of an antifungal agent or of a compound capable of binding to a mannoprotein and blocking the binding of said mannoprotein to an endothelial cell receptor, in the preparation of a pharmaceutical composition for treating a disease associated to an unwanted cell adhesion.... Agent: Universidad Del Pais Vasco

20120093837 - Compositions and methods for detecting egfr in cancer: The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.... Agent: Cell Signaling Technology ,inc. A Corporation

20120093838 - Gene detection assay for improving the likelihood of an effective response to a her2 antibody cancer therapy: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject... Agent:

20120093839 - Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or... Agent: Ablynx N.v.

20120093840 - Targeted delivery of factor viii proteins to platelets: The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods... Agent: Novo Nordisk A/s

20120093842 - Chimeric receptor genes and cells transformed therewith: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The... Agent: Yeda Research And Development Co., Ltd.

20120093841 - Her2 dna vaccine as adjunct treatment for cancers in companion animals: The application discloses therapeutic vaccines based upon the “pING” DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and... Agent:

20120093844 - Antimicrobial peptides based on cmap27: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives... Agent: Universiteit Utrecht Holding B.v.

20120093845 - Neil3 peptides and vaccines including the same: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences.... Agent: Oncotherapy Science, Inc.

20120093846 - Protein for the immunocastration for mammals: DNA sequences coding for said fusion protein; vaccine comprising said fusion protein; use of the fusion protein for mammal immunocastration; process for producing the vaccine; process for preparing the fusion protein that comprises fusing the amino acid sequence of the gonadotrophin-liberating hormone (GnRH-I) to a theoretical glycosilable sequence having immunogenic... Agent:

20120093843 - Tem8 peptides and vaccines comprising the same: According to the present invention, peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 9, 23, 25, 30, 60, 63 or 68 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from the group... Agent: Oncotherpy Science, Inc.

20120093848 - Immunogenic composition comprising peptides derived from cytomegalovirus and the use thereof: The present invention provides (poly)peptides, which are recognized by human cytomegalovirus (CMV)-specific immune cells. The present invention further provides a combination of multiple CMV (poly)peptides, comprising at least two different groups of (poly)peptides according to the invention as well as conjugates, comprising said (poly)peptides and/or immune adjuvants thereof. Furthermore, this... Agent: Vectorite Biomedica Inc.

20120093847 - Recombinant rsv vaccines: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.... Agent: Glaxosmithkline Biologicals

20120093849 - Agents for treatment of hcv and methods of use: An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes... Agent:

20120093851 - Chlamydia antigens: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT1 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C.... Agent:

20120093850 - Compositions for immunising against staphylococcus aureus: Staphylococcus aureus Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens, including Hla polypeptides having... Agent: Novartis Ag

20120093852 - Non-lipidated variants of neisseria meningitidis orf2086 antigens: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup... Agent: Wyeth LLC

20120093853 - Simian adenovirus vectors and methods of use: A recombinant vector comprises a simian adenovirus capsid and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.... Agent: The Trustees Of The University Of Pennsylvania

20120093854 - Use of mycoplasma bovis antigen: The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least one... Agent: Boehringer Ingelheim Vetmedica, Inc.

20120093856 - Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune... Agent: The Gov Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services

20120093855 - Rsv f vlps and methods of manufacture and use thereof: The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs... Agent: Ligocyte Pharmaceuticals, Inc.

20120093858 - Tat-based tolerogen compositions and methods for making and using same: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune... Agent:

20120093857 - Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma: This invention provides a method whereby a vaccine, particularly a vaccine based on a prophylactic or therapeutic AIDS/HIV vaccine, or other immune-reactive substance is administered to produce an immunologic response that decreases intraocular pressure or has a neuro-protective effect beneficial in the treatment of glaucoma patients. The invention may also... Agent:

20120093859 - Influenza vaccine regimens for pandemic-associated strains: In contrast to known regimens where pandemic-associated antigens are given 3-4 weeks apart for immunisation, according to the invention two doses of a pandemic-associated antigen are administered to a human 1 week apart, 2 weeks apart or 6 weeks apart. Thus the invention provides a method for immunizing a human,... Agent: Novartis Ag

20120093860 - Influenza vaccines with increased amounts of h3 antigen: An influenza vaccine includes an increased amount of H3N2 antigen relative to the normal dose. In a typical embodiment, the vaccine includes hemagglutinins from an A/H1N1 strain, an A/H3N2 strain, and a B strain, wherein (i) the weight ratio of H3N2:H1N1 hemagglutinin is greater than 1 and (ii) the weight... Agent: Novartis Ag

20120093861 - Norovirus vaccine formulations: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.... Agent: Ligocyte Pharmaceuticals, Inc.

20120093862 - Nucleic acid vaccines for prevention of flavivirus infection: The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides... Agent: The Government Of The United States Of America As Respresented By The Secretary Of The Department

20120093863 - Hcv vaccines and methods for using the same: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual... Agent:

20120093864 - Methods and compositions for polytopic vaccination: The present invention relates to therapeutic and prophylactic methods for treating Or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a... Agent: Polytopos LLC

20120093865 - Compositions comprising reduced genome bacteria for use in treatment of sepsis: Methods for prophylaxis or treatment of sepsis in a subject are provided comprising administering to the subject a therapeutically effective dose of multiple deletion strain bacteria.... Agent: Scarab Genomics LLC

20120093866 - Formulation for stabilizing proteins, which is free of mammalian excipient: The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, and wherein the formulation is free of stabilizing proteins.... Agent: Merz Pharma Gmbh & Co. Kgaa

20120093867 - Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.... Agent:

20120093868 - Haemophilus influenzae type b: Polypeptides comprising various amino acid sequences derived from Haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis. They may also be useful for diagnostic purposes, and as targets for antibiotics. Antibodies against the polypeptides are... Agent: Novartis Vaccines And Diagnostics Srl

20120093870 - Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto: An attenuated enterohemorrhagic E. coli-based vaccine vector is disclosed. Enterotoxigenic E. coli colonization factor antigen 1 and the B subunit of E. coli heat labile toxin have been expressed in the attenuated enterohemorrhagic E. coli vector strain. Immunized animals are further protected against lethal and non lethal challenges with the... Agent: Stc.unm

20120093869 - Live-attenuated compositions for bacterial infections: The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity.... Agent:

20120093871 - Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof: Modified protozoa parasites comprising simultaneous expression on its surface of at least two ariable surface proteins (VSP). The modified protozoa may also simultaneously express the complete repertoire of variable surface proteins. Protozoa show reduced expression of Dicer, RNA-dependant RNA-plymerase (RdRP) enzymes or both, wherein the RdRP gene and/or the Dicer... Agent:

20120093872 - Method for polypeptide transfer into cells: The present invention relates to a method for polypeptide transfer into cells. The present invention further relates to the detection of polypeptide-specific immune cells and the priming, expansion and reactivation of polypeptide-specific T cells. Moreover the present invention relates to polypeptides of the methods of the present invention in combination... Agent: Lophius Biosciences Gmbh

20120093874 - Method for screening for diet providing production of milk having immunoregulatory action: A method for screening for a foodstuff providing production of milk having an immunoregulatory action, a novel foodstuff having an immunoregulatory action, and a method for producing it are provided. A diet or substance that increases or decreases an amount of microRNA present in milk of a mammal is identified... Agent: Morinaga Milk Industry Co., Ltd.

20120093873 - Molecular interactions in hematopoietic cells: The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.... Agent: Arbor Vita Corporation

20120093875 - Aminocyclitol compounds, process for obtaining them and uses: Aminocyclitol compounds and uses thereof as pharmaceutical compositions for the treatment of diseases associated with alterations in iNKT cells, more specifically autoimmune diseases, cancer, infections caused by pathogenic microorganisms or inflammatory diseases. Furthermore, the invention relates to the process for obtaining said compounds.... Agent:

20120093888 - micro-emulsions for the treatment of rheumatic disorders: A formulation to treat rheumatic disorders and related infections is provided. The formulation is a micro-emulsion including at one or more of an active ingredients. The active ingredient includes one or more of an essential oil mixed with an aqueous phase along with one or more of a surfactant and... Agent:

20120093887 - Amorphous varenicline tartrate co-precipitates: Disclosed herein is a stable amorphous coprecipitate comprising varenicline tartrate and a pharmaceutically acceptable excipient selected from the group consisting of maltodextrin, lactose monohydrate and 2-hydroxypropyl-β-cyclodextrin, method for the preparation, pharmaceutical compositions, and method of treating thereof. Advantageously, the amorphous coprecipitates of varenicline tartrate disclosed herein have improved physiochemical characteristics... Agent: Actavis Group Ptc Ehf

20120093895 - Bone-repair composition: The present invention relates to a bone-repair composition comprising a micro-pulverized demineralized bone matrix; a nonmicro-pulverized demineralized bone matrix; and a hydrating material. The bone-repair composition of the present invention provides easier injectability and shape-maintenance (handling), and exhibits excellent bone-repairing effects due to a large surface area of the micro-pulverized... Agent: Cg Bio Co. Ltd.

20120093879 - Cardiac stem cells and uses of same in cardiac repair: Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and... Agent: Universita Degli Studi Di Roma "la Sapienza"

20120093877 - Collagen scaffold for cell growth and a method for producing same: A bioscaffold and method of manufacture is described. The bioscaffold comprised greater than 80% type I collagen fibers or bundles having a knitted structure providing tensile load strength. The method of manufacture comprises the steps of: (a) isolating collagen fibers or bundles; (b) incubating said fibers or bundles in a... Agent: The University Of Western Australia

20120093881 - Disruptive polymer micelle composition: A pharmaceutical composition containing a drug encapsulated in a polymer micelle composition containing a first block copolymer having affinity with HDL and a second block copolymer having affinity with a lipoprotein excluding HDL, each block copolymer having a hydrophobic polymer chain segment and a hydrophilic polymer chain segment such that... Agent: Nanocarrier Co., Ltd.

20120093893 - Highly efficient delivery of a large therapeutic mass aerosol: p

20120093890 - Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans,... Agent: Gilead Sciences, Inc.

20120093889 - Layered pharmaceutical formulations: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one... Agent: Orexigen Therapeutics, Inc.

20120093891 - Macrocyclic lactone compounds and methods for their use:

20120093880 - Method and kit for topical elimination of psoriatic lesions with a caustic applicator: A method and kit for eliminating a psoriatic lesion involves removal of loose psoriatic scales if present, and moistening remaining scales to a depth to or just above epidermal tissue underlying the scales. The hydrated scales are then contacted with a dry composition of from about 50% to about 95%... Agent:

20120093883 - Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions: A method for treating at least one of neuro-olfactory triggered illnesses, and related conditions within a subject is provided. The method includes the steps of: a) providing a composition that includes one or more agents adapted to induce a level of anosmia/hyposmia in the subject, which level of anosmia/hyposmia is... Agent:

20120093892 - Minocycline oral dosage forms for the treatment of acne: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.... Agent: Medicis Pharmaceutical Corporation

20120093884 - Norovirus capsid and rotavirus vp6 protein for use as combined vaccine: The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and/or viral-induced diarrheal and vomiting diseases in man. More specifically, the invention comprises a method of preparing combination vaccine compositions comprising norovirus and rotavirus antigens, in particular mixtures of norovirus VLPs and... Agent:

20120093876 - Ophthalmic formulations, methods of manufacture and methods of normalizing meibomian gland secretions: The present invention provides process for producing non-aqueous compositions for normalizing meibomian gland secretions. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of dry eye disease.... Agent: Aciex, Inc.

20120093886 - Pharmaceutical compositions and related methods of delivery: The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The... Agent:

20120093878 - Pharmaceutical compositions containing a biguanide and a thiazolidinedione: The present invention relates to pharmaceutical compositions that include a combination of a biguanide present in an extended-release form and a thiazolidinedione present in an immediate-release form. The present invention further relates to the processes for preparing such compositions.... Agent: Ranbaxy Laboratories Limited

20120093894 - Stable cyclosporine containing ophthalmic emulsion for treating dry eyes: Disclosed herein are stable oil-in-water emulsion ophthalmic topical liquid compositions having an average particle size less than 1 μm including at least one plant-derived oil other than castor oil wherein the oil comprises only aliphatic side chains free of polar pendent groups. The oil-in-water emulsion ophthalmic topical liquid compositions also... Agent: Abbott Medical Optics Inc.

20120093882 - Stable pharmaceutical compositions of diclofenac: The present invention discloses a stable pharmaceutical composition of diclofenac or salts thereof comprising nano size droplets of diclofenac or salts thereof, wherein the composition exhibits a significant difference in one or both of the rate and extent of absorption of diclofenac or salts thereof as compared to formulation of... Agent:

20120093885 - Therapeutic vesicles: The present technology provides compositions of vesicles, uses of vesicles, and methods relating to vesicles. For example, provided herein are vesicles derived from stem cells for use in regenerative therapies.... Agent: Northwestern University

20120093900 - Capillary composition for treating hair: The invention relates to a capillary composition comprising at least particles of pumice, at least one silicon containing quaternary ammonium groups, and at least one non-siliconised polymer.... Agent: L'oreal

20120093904 - Composition comprising an anionic polymeric material and the salt of a saturated monocarboxylic acid having 6 to 22 carbon atoms: The invention relates to a coating composition for the coating or binding of pharmaceutically, nutraceutically or cosmetically active ingredients, comprising (a) an anionic polymeric material, and (b) one or more salts of saturated monocarboxylic acids having 6 to 22 carbon atoms, characterized in that the amount of the salts of... Agent: Evonik Roehm Gmbh

20120093902 - Fluid reservoir: Fluid reservoirs which are based on polymer substrates and are capable of storing large amounts of fluids. The storage is reliable and the reemergence from the liquid reservoir is readily controllable, for example, via the temperature or via mechanical actions, to achieve retardation of the fluid release. Also, processes for... Agent: Henkel Ag & Co. Kgaa

20120093898 - Metal ion nanoclusters: A composition containing a plurality of water-soluble nanoclusters ranging from 2 nm to 500 nm in diameter. Each of the nanoclusters contains one or more metal cations, one or more anions, and one or more water-soluble ligands. Also disclosed is a method of using the composition for treating various disorders... Agent: Lg Bionano, LLC

20120093901 - Method for producing free powder particles of polyamide impregnated with at least one cosmetic or pharmaceutical agent, and free powder particles of polyamide having a content of at least 25 wt % of a cosmetic or pharmaceutical agent other than water: The invention relates to a method for producing free powder particles of polyamide impregnated with at least one cosmetic or pharmaceutical agent. The present also relates to free powder particles of polyamide having a content of at least 25% by weight of a cosmetic or pharmaceutical agent other than water,... Agent: Arkema France

20120093905 - Oral care compositions comprising a polymeric dye: An oral care composition comprising a dye polymer, for modifying the colour of teeth.... Agent:

20120093903 - Powdery or granulated composition comprising a copolymer, a salt of a fatty monocarboxylic acid and a fatty monocarboxylic acid and/or a fatty alcohol: The invention relates to a powdery or granulated composition comprising at least by 30% by weight of a mixture of (a) a copolymer composed of polymerized units of C1- to C4-alkyl esters of acrylic or methacrylic acid and of alkyl(meth)acrylate monomers with a tertiary amino group in the alkyl radical... Agent: Evonik Roehm Gmbh

20120093899 - Process for preparing a high stability microcapsule product and method for using same: The present invention is directed to a process for preparing a capsule product through the increase in the polymerization cure temperature and cure time during the capsule-making process. The microcapsule products prepared according the process of the present invention exhibit enhanced retention of active materials in consumer products which promote... Agent:

20120093897 - Skin engaging member comprising an emollient: A skin engaging member for use with a hair removal device, said skin engaging member comprising: a carrier comprising a pair of opposing sidewalls forming a channel; and at least one skin conditioning composition at least partially contained within said channel, wherein said skin conditioning composition comprising: at least one... Agent:

20120093896 - Use of nanodispersions to protect water-soluble ingredients in cosmetic end formulations: The invention describes the use of a nanodispersion, which comprises: a) a membrane-forming molecule, b) a co-emulsifier, c) a lipophilic component, and d) a water-soluble ingredient sensitive to oxidation in cosmetic end formulations, the nanodispersion being obtainable by (α) mixing the components (a), (b) and (c) until a homogeneous liquid... Agent: Ciba Corporation

20120093906 - Emulsions, emulsifier, method of use and production process: Emulsions, emulsifier, a method of use and a production process of said emulsions are presented in the present invention. The emulsion composed of a mixture of water and oils and additives sheared into small droplets using a low pressure, three shearing stage emulsifier. The oils used in the preparation of... Agent:

20120093907 - Composite of silver nanoparticle and layered inorganic clay for inhibiting growth of silver-resistant bacteria: The present invention provides a composite of spherical silver nanoparticles and layered inorganic clay. This composite can effectively inhibit the growth of silver-resistant bacteria. The layered inorganic clay serves as carriers of the silver nanoparticles and disperses them. The composite has a particle size of about 5 nm to 100... Agent: National Taiwan University

20120093908 - Metal oxide sterilizing catalyst, and sterilizing device and system including the same: Disclosed is a sterilizing catalyst, a sterilizing device and a sterilizing system, the sterilizing catalyst includes a metal lattice including a metal oxide, and an oxygen vacancy-inducing metal that is integrated or encompassed within the metal lattice. The metal oxide is an oxide of a divalent or multivalent metal. The... Agent: Samsung Electronics Co., Ltd.

20120093909 - Ceramic coatings and applications thereof: In one aspect, the present invention provides coated metal substrates which, in some embodiments, demonstrate one or more advantageous chemical and/or mechanical properties.... Agent:

20120093910 - Non-hormonal vaginal contraceptive: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the... Agent:

20120093911 - Platinum-catalyzed intravaginal rings: The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of an antimicrobial compound, e.g., Dapivirine, to a human. The intravaginal rings of the invention address previous stability issues by utilizing a platinum catalyst (e.g., in the form of a platinum-siloxane complex) for... Agent: International Partnership For Microbicides

20120093912 - Biomimetic nanofiber web and method and device to manufacture the same: A method for forming nanofiber web comprises the steps of: mixing (21) polymeric material with a solvent to obtain a liquid mixture having a viscosity above a predetermined shear viscosity value at room temperature; feeding (23) a spray nozzle with said mixture; projecting (25) said mixture through said nozzle with... Agent: Universite De Nantes

20120093918 - Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof: A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the... Agent: Socpra - Sciences Sante Et Humaines

20120093916 - Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions... Agent:

20120093919 - E2f as a target of hormone refractory prostate cancer: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.... Agent: University Of Medicine And Dentistry Of New Jersey

20120093921 - Immunogenic compositions having low sodium chloride concentration: Immunogenic compositions comprising an antigen, wherein the concentration of sodium chloride or the ionic strength of the composition is less than 100 mM, and their use in medicine, are provided.... Agent: Glaxosmithkline Biologicals S.a.

20120093914 - Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration: In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments,... Agent: Moma Therapeutics

20120093913 - Inhibition of syk kinase expression: The present invention relates, in general, to Syk kinase and, in particular, to a method of inhibiting Syk kinase expression using small interfering RNA (siRNA).... Agent: The Trustees Of The University Of Pennsylvania

20120093920 - Method of treatment for bladder dysfunction: Liposomes are used for intravesical drug delivery, especially delivery of botulinum toxin (BoNT) to help improve lower urinary tract symptoms by decreasing bladder irritation and frequency. The system uses a lower and safer dose of BoNT with lower risk of urinary retention. A simple instillation of liposome-BoNT as a liquid... Agent: Lipella Pharmaceuticals Inc.

20120093917 - Metnase and intnase inhibitors and their use in treating cancer: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical inhibitors of DNA repair proteins (Metnase) and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols.... Agent:

20120093915 - Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids: The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.... Agent: Universite Paris Descartes

20120093923 - Apparatus and methods for delivering a plurality of medicaments for management of co-morbid diseases, illnesses, or conditions: A method and apparatus for delivering a plurality of medicaments in a single delivery vehicle for the management of co-morbid diseases, illnesses and conditions. The present invention provides a novel delivery process for many medicaments. Medicaments may be encapsulated and stored separately within a larger capsule until the time of... Agent: Innercap Technologies, Inc.

20120093924 - Methods of treating hypertriglyceridemia: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharma, Inc.

20120093925 - Oral medicinal composition and oral medicinal capsule having the composition encapsulated therein: The present invention relates to an oral medicinal composition comprising (a) a medical agent that is low in solubility in both water and oils but is soluble in a polyethylene glycol, (b) a polyethylene glycol that is solid at temperatures of 40° C. or lower, and (c) an oily or... Agent: Morishita Jintan Co., Ltd.

20120093922 - Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.... Agent: Amarin Corporation PLC

20120093926 - Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid: The invention relates to a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the release of the pharmaceutical or nutraceutical active ingredient is not more than 15% under in-vitro conditions at pH... Agent: Evonik Roehm Gmbh

20120093927 - 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine): Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.... Agent:

20120093928 - Oral metaxalone compositions: The present invention relates to a pharmaceutical composition comprising low-dose metaxalone and one or more pharmaceutically acceptable polymer, as well as methods of preparing them.... Agent: Ranbaxy Laboratories Limited

20120093930 - Article and method for focused delivery of therapeutic and/or diagnostic materials: A microfiber extrudate and delivery process includes a bio-compatible polymer matrix forming a body of the microfiber extrudate, an exogenously excitable material arranged within the body, and an active load arranged within the body.... Agent: Armark Authentication Technologies, LLC

20120093929 - Opioid composition for treating skin lesions: The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.... Agent: Euro-celtique S.a.

20120093933 - Denatured lactoglobulin and polyphenol coassemblies: The present invention is directed to co-assembled nanoparticle composition comprising denatured β-lactoglobulin and at least one nutraceutical compound, specifically polyphenols, such as EGCG, compositions comprising same and methods of preparing thereof.... Agent: Technion Research And Development Foundation Ltd.

20120093931 - Inhibition of neovascularization by cerium oxide nanoparticles: The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving neovascularization by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the invention is useful, for example, for reducing, treating, reversing... Agent:

20120093932 - Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof: A targeted sustained-release microsphere vascular embolizing agent, the production method and the use thereof are disclosed. The microsphere comprises sodium alginate as the carrier and sorafenib as the targeted anti-tumor medicine and sorafenib is encapsulated by sodium alginate. The weight ratio of sorafenib to sodium alginate is 1:1˜1:30. The microspheres... Agent: Beijing Shengyiyao Science & Technology Development Co., Ltd.

20120093934 - Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres: The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present... Agent: Uti Limited Partnership

20120093935 - Particles having a luminescent inorganic shell, method for coating particles and use thereof: The invention relates to a method for coating particles with a luminescent inorganic shell. Furthermore, the invention relates to particles having a luminescent inorganic shell and also use thereof.... Agent: Fraunhofer-gesellschaft Zur Forderung Der Angewandten Forschung E.v.

20120093937 - Encapsulated liver cell composition: Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin.... Agent:

20120093936 - Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system: The present invention relates to methods and compositions for use in the treatment of specific medical conditions. The compositions of the invention comprise blood serum preparations, such as activated blood serum preparations. The present invention also relates to the use of such blood serum preparations for the treatment of diseases... Agent: Velin-pharma A/s

20120093938 - Orally disintegrating tablets comprising diphenhydramine: The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These... Agent: Eurand Inc.

20120093939 - Oral formulations: Disclosed are pharmaceutical compositions comprising immediate release and sustained release formulations of 5-aminosalicylic acid, or a pharmaceutically acceptable salt or ester thereof, and/or N-acetylcysteine, or a pharmaceutically acceptable salt or ester thereof, for release in the lower gastrointestinal tract.... Agent: Altheus Therapeutics, Inc.

20120093940 - Medical food or nutritional supplement for managing blood glucose levels and method of manufacturing same: A medical food and/or nutritional supplement for oral administration by mammals includes α-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacturing the medical food or nutritional supplement is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components,... Agent: Response Scientific, Inc.

20120093941 - Neutrophil-depleted platelet rich plasma formulations for cardiac treatments: Compositions and methods for preparing neutrophil-depleted platelet rich plasma are provided. Generally, these compositions comprise a higher concentration of platelets and depressed concentrations of neutrophils relative to whole blood although white blood cells may be at higher concentrations than whole blood. The concentrations of the platelets and/or the white blood... Agent:

20120093942 - Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts: Disclosed is a pharmaceutical composition and health food comprising herb extracts of one or more herbs selected from the group consisting of Puerariae Radix, Bombycis corpus and Araliae Continentalis Radix. The herb medicine of this invention comprising a single or mixed composition may be useful for the prevention and treatment... Agent: Dong Wha Pharm. Co., Ltd.

20120093943 - Pharmaceutically active compounds, their manufacture, compositions containing them, and their use: A substance for use as a medicament, comprises a solid mixed metal compound of formula (I): MII1-aMIIIaObAn−c.zH2O (I) where MII is at least one bivalent metal: MIII bis at least one trivalent metal; An− is at least one n-valent anion; 2+a=2b+Σcn; and Σcn<0.9a. The substance may be made by heating... Agent:

20120093944 - Method for surface inclusions detection, enhancement of endothelial and osteoblast cells adhesion and proliferation, sterilization of electropolished and magnetoelectropolished nitinol surfaces: The method for surface inclusions detection, enhancement of endothelial and osteoblast cells adhesion and proliferation and sterilization of electropolished and magnetoelectropolished Nitinol implantable medical device surfaces uses an aqueous solution of chemical compounds containing halogenous oxyanions as hypochlorite (ClO−) and hypobromite (BrO−) preferentially 6% sodium hypochlorite (NaClO).... Agent:

20120093945 - Method for treating an inflammation or lesion caused by a virus: A method for treating an inflammation or lesion caused by herpes virus, comprising topically applying to said inflammation or lesion a composition consisting essentially of a C1 to C3 monohydroxy alcohol or a C2 to C4 diol and a sufficient amount of an acid to adjust the pH of the... Agent: Life Force Technologies, LLC

20120093946 - Use of carbon dioxide supplying means for muscle strengthening and method of increasing cattle meat thereby: Use of a carbon dioxide-supplying means for muscle strengthening makes it possible conveniently to strengthen a target muscle within a short period of time merely by allowing the target site to absorb carbon dioxide without loading any mechanical burden on the target muscle. By loading a mechanical burden on the... Agent:

20120093947 - Method of treating reactive airway disease: A method of treating a reactive airway disease in a subject comprising administering at least one peroxidase inhibitor in association with administration of at least one β-agonist.... Agent: University Of Cincinnati

20120093948 - Nitric oxide treatments: Portable and pure nitric oxide delivery systems can be used to treat a variety of patient conditions.... Agent:

20120093949 - Systems and methods for treating lice: A method of treating lice includes the steps of: (a) blending a treatment mixture; (b) applying the treatment mixture to a scalp or hair; and (c) applying a first shampoo to the scalp or the hair. The treatment mixture used in this method may contain olive oil and dimethicone. The... Agent:

20120093950 - Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occuring age related erectile dysfunction: Compositions for treating erectile dysfunction (“ED”), including age related erectile dysfunction (ARED), comprise in a preferred embodiment ginger and an amino acid. Preferably the amino acid is L-arginine and/or L-citrulline. Additionally, the compositions may comprise cortex magnoliae officinalis (CMO) and/or fructus aurantil immaturus (FAI). The compositions of the present inventions... Agent: Klrm, LLC

20120093951 - Traditional chinese medicine composition for treating swine influenza, preparation method and use thereof: The present invention relates to a traditional Chinese medicine composition for preventing and treating swine influenza, preparation method and use thereof. The said traditional Chinese medicine composition is made from Herba Houttuyniae 21.4 wt. %, Caulis Lonicerae Japonicae 17.9 wt. %, Radix Isatidis 14.3 wt. %, Rhizoma Dryopteris Crassirhizomatis 10.7%,... Agent:

20120093952 - Use of essential oil compounds as histomonastat: The present invention relates to the use of essential oil compounds as histomonastats. An example of a essential oil compound of the invention is cinnamaldehyde.... Agent:

20120093953 - Magnolia extract containing compositions: Disclosed is a method of treating telangiectasias on a person's skin comprising topically applying to skin in need of treatment a composition comprising magnolia bark extract.... Agent:

20120087858 - Dual variable domain immunoglobulins and uses thereof: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.... Agent: Abbott Laboratories.

20120087857 - Gadolinium expressed lipid nanoparticles for magnetic resonance imaging: Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging.... Agent: University Of Washington

20120087859 - Nanocarrier having enhanced skin permeability, cellular uptake and tumour delivery properties: The present invention relates to a biopolymer-modified nanocarrier in which chitosan is bound to a water-soluble biocompatible polymer that has been crosslinked via a photo-crosslinkable functional group; wherein the chitosan-modified nanocarrier has a diameter which changes in accordance with changes in temperature, has enhanced skin permeability or cellular uptake and... Agent: Gwangju Institute Of Science And Technology

20120087861 - Human anti-tau antibodies: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used... Agent:

20120087860 - Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags: In another embodiment, a method for detecting and/or diagnosing a cancer in a subject is provided. The method may include administering an effective dose of a biotag to a subject, or alternatively, administering an effective dose of a targeted contrast to the subject, the targeted contrast comprising a contrast agent... Agent:

20120087862 - Organ-specific proteins and methods of their use: The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific proteins and transcripts encoding the same, detection reagents for detecting such proteins and transcripts, and diagnostic panels, kits and arrays for measuring organ-specific proteins/transcripts in blood, biological... Agent: Institute For Systems Biology

20120087863 - Peptide derivative and use of the same: e

20120087864 - Method for diagnosing and/or evaluating retinal disease: The present application provides a method for diagnosing and/or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and/or evaluating circulatory parameters, retinal function, retina morphology and/or visual relating quality of life (QOL).... Agent: R-tech Ueno, Ltd.

20120087866 - Needle array assembly and method for delivering therapeutic agents: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to... Agent:

20120087865 - Treatment of ischemia: A system, including methods and compositions, for treatment of ischemia.... Agent: Morehouse School Of Medicine

20120087867 - Method for the generation of nuclear hyper-antipolarization in solids without the use of high magnetic fields or magnetic resonant excitation: A method of inducing nuclear spin hyper-antipolarization in a solid material is disclosed and described. The solid material can be subjected to an ultralow temperature and a magnetic field. The solid material can include donor nuclei and a carrier material while the material also has both a nuclear spin and... Agent:

20120087868 - Nanoparticle-loaded cells: The invention provides nanoparticle-loaded cells and compositions useful for improved imaging and therapy, for example radio-therapy. The invention also provides methods of manufacture of nanoparticle-loaded cells, methods of administering the nanoparticle-loaded cells, and methods for treatment and/or imaging.... Agent:

20120087869 - Methods for distributing agents to areas of brain: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.... Agent: Medtronic, Inc.

20120087870 - Novel caviidae allergens and uses thereof: The present invention relates to the provision of a nucleic acid molecule encoding a Caviidae allergen comprising a polynucleotide selected from the group consisting of (a) a polynucleotide sequence as shown in SEQ ID NO 1 (Cav p 3), SEQ ID NO 5 (Cav p 2), SEQ ID NO 3... Agent:

20120087872 - Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.... Agent: Foamix Ltd.

20120087871 - Wasp, hornet, and yellowjacket spray repellant and nest pesticide: Methods for killing insects and a nest are disclosed. The methods may be used to disrupt a colony of nestdwelling insects. The insects may include wasps, hornets, and yellowjackets.... Agent: Sterling International Inc.

20120087873 - Urea foam: Provided, among other things, is a delivery module for a non-greasy, water-based urea composition comprising: an aerosol delivery device; within the aerosol delivery device, the urea composition comprising 20% or more urea by weight, non-greasy lipophilic component(s), and a frothing agent, the urea composition having a viscosity low enough to... Agent: Quinnova Pharmaceuticals, Inc.

20120087875 - Buffered gum base for high ph release: A chewing gum composition with high pH-release includes an insoluble gum base matrix and a soluble bulk portion, wherein the gum base matrix and the bulk portion is mixed and extruded to form a final chewing gum core, and wherein the gum base matrix is buffered before mixing with the... Agent:

20120087874 - Warming compositions and delivery systems therefor: The present invention includes compositions for imparting a controlled-release warming sensation to the oral receptor areas of a user. The oral, controlled-release warming compositions include a warming agent and a hydrated or swollen food-grade polymer which forms a matrix with the warming agent. Also included are oral delivery systems for... Agent:

20120087876 - Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.... Agent: Galderma, S.a.

20120087878 - Botanical formulations: Disclosed is a method of reducing melanogenesis in a skin cell, comprising topically applying to skin in need of treatment a composition comprising navy bean extract, wherein topical application of the composition to skin reduces melanogenesis in said skin cell.... Agent:

20120087877 - Composition based on mineral concentrates derived from precious stones: The invention relates to a composition based on mineral concentrates and a method of preparing this composition. The composition comprises a powder or a mixture of powders containing at least one silicon derivative and at least one trace element other than silicon, as a mixture with a carrier and physiologically... Agent: Bulgari Parfums

20120087879 - Bleaching composition comprising a non-volatile liquid branched ester of carboxylic acid with solidification point below 4°c: The present disclosure relates to compositions for the bleaching of keratinous fibers comprising at least one peroxygenated salt and at least one non-volatile liquid branched ester of a carboxylic acid, the solidification point of which is below 4° C., chosen from the compounds with the following structure: R1—CO—O—R2, wherein R1... Agent: L'oreal S.a.

20120087880 - Novel 3.2.1-bicyclo-octane compounds: e

20120087881 - Safe & easy:

20120087882 - Cationic polyglyceryl compositions and compounds: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently... Agent:

20120087883 - Shampoo composition containing a conditioning gel network: Conditioning shampoo composition with an oil selected from polyalphaolefin oils, ester oils, triglyceride oils, hydrocarbon oils and mixtures thereof dispersed therein, the composition comprising from 1-26% wt. cleansing phase, a conditioning gel network, a polymeric suspending agent and a cationic deposition polymer.... Agent:

20120087884 - Novel 3.2.1-bicyclo-octene and -octane compounds: n

20120087885 - Novel 3.2.1-bicyclo-octane compounds:

20120087886 - Novel 3.2.1-bicyclo-octene and -octane compounds:

20120087888 - Bio-mechanical stimulation of collagen synthesis in skin cells and reduction of appearance of fine lines and wrinkles on the skin: The present invention achieves bio-mechanical stimulation of collagen synthesis in skin cells and reduction of the appearance of fine lines and wrinkles on the skin by applying a polymeric composition onto the skin in a manner so as to create surface tension that mimics the natural mechanical tension found in... Agent:

20120087887 - Composition and method for arresting blood flow and for forming a persistent microbial barrier: A composition and method useful in promoting healing of a bleeding wound site. The composition preferably includes a substantially anhydrous acid form of a cation exchange resin, which when applied over blood, provides an antimicrobial against planktonic microorganisms and biofilms in the wound. The resin is also capable, when applied... Agent: Biolife, L.L.C.

20120087889 - Plant volatiles based on r-curcumene: The invention provides a method for controlling whiteflies which comprises the steps of: providing a composition comprising or consisting of R-curcumene and optionally further beta-myrcene, para-cymene, gamma-terpinene, alpha-terpinene, alpha-phellandrene zingiberene and/or 7-epi-zingiberene; and adding said composition one or more times to a plurality of crop plants. The method can be... Agent: Keygene N.v.

20120087892 - Identification of dsg-3 as a biomarker for the detection of metastasis in lymph nodes: Disclosed herein is a method of detecting metastasis of a tumor in a subject, such as metastasis to a lymph node. The method includes directly determining an amount of desmoglein-3 (DSG-3) protein in a sample from the subject (such as a lymph node sample) and comparing the amount of DSG-3... Agent:

20120087890 - Immunonanotherapeutics that provide igg humoral response without t-cell antigen: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers... Agent: Massachusetts Institute Of Technology

20120087891 - Reversible gel-forming compositions for controlled delivery of bioactive substances: The present invention relates biomedically useful compositions containing bioactive agents and biodegradable carbohydrate polyethers that exhibit reverse thermogelation properties in aqueous media. The microstructure structure and properties of the carbohydrate polyethers can be conveniently controlled with respect to functionality, molecular weight, polydispersity index, microstructure and tertiary structure, they can be... Agent:

20120087893 - Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and... Agent: Ptc Therapeutics, Inc.

20120087894 - Producer cells for replication competent retroviral vectors: The disclosure provide cell lines and methods for the production of vectors and viral particles useful in gene therapy.... Agent: Tocagen, Inc.

20120087901 - Engineered mesenchymal stem cells and methods of using same to treat tumors: This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein... Agent: Apceth Gmbh & Co. Kg

20120087900 - Immunotherapeutic agent: The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby... Agent: Catholic University Industry Academic Cooperation Foundation

20120087896 - Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays: Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent:

20120087895 - Probiotic therapies for autism: Provided is a method and a composition for improving behavioral performance in an individual comprising identifying an individual in need of treatment, and providing such an individual a composition comprising bacteria within the genus Bacteroides.... Agent:

20120087902 - Therapeutic use of probiotics: The involvement of intestinal microbiota in the initiation and perpetuation of inflammatory bowel disease is widely accepted. To reestablish the homeostasis of the gut the use of probiotics has been proposed, with however, limited clinical benefit. This invention relates to an assay based on the modulation of the immunological activity... Agent: Bracco S.p.a.

20120087897 - Grass based avian deterrent: The invention relates to uses and methods relating to grass and endophyte combinations to repel avian species from the grass and endophyte combination. In particular, methods are described to select grass and endophyte combinations in order to enhance or maximise the repellent effect. Preferred endophyte and grass combinations are described... Agent:

20120087898 - Compositions comprising female germline stem cells and methods of use thereof: The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.... Agent: The General Hospital Corporation

20120087899 - Heparan sulphate: Heparan sulphate from bone marrow stroma is disclosed together with the use of heparan sulphate from bone marrow stroma in the differentiation and/or lineage commitment of stem cells.... Agent: Agency For Science, Technology And Research

20120087903 - Hair growth agent having a platelet dry powder: A hair growth agent having an effective dose of a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, wherein the effective dose refers to the presence of at least 1,000 platelets in every milligram of the hair growth agent.... Agent: Central Medical Technologies Inc.

20120087904 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.... Agent: Amderma Pharmaceuticals, LLC

20120087908 - Factor vii composition: The invention relates to a stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant.... Agent: Lfb-biotechnologies

20120087906 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent:

20120087907 - Prothrombic complex composition: The present disclosure relates to a method for preparing a composition or a concentrate of a prothrombic complex that includes the II, VII, IX and X coagulation factors, including providing a supernatant of a plasma cryoprecipitate, applying the supernatant on an anion-exchange resin for producing an eluate containing the complex... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa

20120087905 - Treatment of diseases related to hyperactivity of the complement system: Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described.... Agent: Cambridge Enterprise Limited

20120087911 - Crystal structure: This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.... Agent: Rsr Limited

20120087909 - Neutralizing monoclonal antibodies to respiratory syncytial virus: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated... Agent:

20120087910 - Sparc angiogenic domain and methods of use: The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain.... Agent: Abraxis Bioscience, LLC

20120087912 - Treatment methods using dkk-1 antibodies: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable... Agent: Amgen Inc.

20120087916 - Anti-icam-1 antibody, uses and methods: The present invention relates to an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, and to the use thereof in medicine for the treatment of cancers, such as multiple myeloma.... Agent:

20120087913 - Induction of tumor hypoxia for cancer therapy: Methods and compositions for enhancing the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors are provided. Local regions of hypoxia are created within a tumor, or within a region containing a tumor, resulting in enhanced activation of hypoxia-activated bioreductive agents (e.g. tirapazamine) within the local region.... Agent:

20120087914 - Inhibition of trim62 activity reduces cancer cell proliferation: The present invention provides methods to treat cancers using inhibitors of the TRIM62 protein and methods to identify inhibitors and other modulators of the TRIM62 protein. Pharmaceutical compositions that contain an inhibitor of a TRIM62 protein are also provided.... Agent: Fred Hutchinson Cancer Research Center

20120087917 - Lox and loxl2 inhibitors and uses thereof: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a... Agent:

20120087918 - Methods and compositions for inhibiting the growth of hematopoietic malignant cells: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic... Agent: A & G Pharmaceutical, Inc.

20120087915 - Use of inhibitors of bruton's tyrosine kinase (btk): Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more... Agent: Pharmacyclics, Inc.

20120087920 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20120087919 - Method for treating diabetes: Fusion proteins binding specifically to cell types of the islets of Langerhans and delivering therapeutic or prophylactic agents are provided herein, as well as compositions thereof. Methods for treating or preventing diseases related to the pancreas such as diabetes are also disclosed. The therapeutic or prophylactic agents include Nemo-binding domain... Agent: The Royal Institution For The Advancement Of Learning/mcgill University

20120087921 - Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer: Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.... Agent: Biokine Therapeutics Ltd.

20120087923 - Antibodies to opgl: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.... Agent: Amgen Inc.

20120087922 - Dr5 antibodies and uses thereof: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.... Agent:

20120087925 - Method for the treatment of inflammatory disorders: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.... Agent: Biogen Idec Ma Inc.

20120087924 - Recombinant b. pseudomallei adhesin protein and methods and uses thereof: Isolated and/or recombinant adhesin polypeptides from Burkholderia pseudomallei are provided, which are used as vaccines. Genetic constructs comprising nucleic acid sequences encoding such polypeptides are also provided. Vectors comprising such constructs have been prepared and used for transforming host cells for producing the polypeptides of the invention. Antibodies to such... Agent: Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defense

20120087926 - Chicken-derived anti-lox-1 antibody: Anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity are obtained. The anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity have been obtained, the antibodies being which specifically binds to a LOX-1 and having heavy chain CDR3 comprising one or more amino acid sequences selected from the... Agent: Basf Coatings Gmbh

20120087927 - Antibody containing igg2 having amino acid mutation introduced therein: The present invention can provide a monoclonal antibody which comprises a heavy chain constant region which is IgG2 wherein valine at position 234, glutamine at position 237 and proline at position 331 are at least substituted with alanine, alanine and serine, respectively (numbering is based on the EU index of... Agent: Kyowa Hakko Kirin Co., Ltd

20120087928 - Therapeutics for age-related macular degeneration: The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.... Agent:

20120087929 - Vegf antagonist formulations for intravitreal administration: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence of residues 27-457 of SEQ ID NO:4.... Agent: Regeneron Pharmaceuticals, Inc.

20120087930 - Marker of streptococcus anginosus/ streptococcus constellatus (moac) and uses thereof: The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting Streptococcus strains of the anginosus group, preferably for detecting Streptococcus anginosus and/or Streptococcus constellatus as well as for discriminating Streptococcus anginosus and/or Streptococcus constellatus from other streptococci. The present invention furthermore relates to these... Agent:

20120087931 - Therapeutic and diagnostic anti-hsp70 antibodies: Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue... Agent:

20120087934 - Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis: The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active... Agent: Merrimack Pharmaceuticals, Inc.

20120087932 - Diagnostic test for virus: Unique Avian Nephritis Virus (ANV) nucleic acid sequences have been determined. Primers and probes have been developed using the isolated nucleic acid sequences and a reverse transcription PCR has been developed to detect the presence of ANV in commercial flocks. Furthermore, use of the nucleic acid sequences and amino acids... Agent: Agri-food Biosciences Institute

20120087933 - Enhanced msc preparations: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of... Agent:

20120087935 - Serine rich peptides having antioxidative stress properties: The present invention relates to novel serine rich peptides capable of exhibiting antioxidative properties and that can be used to protect a cell, tissues, organs or a multi-cellular organism, such as animals, against oxidative stress. In aspects of the invention, the peptides may be derived from egg yolk proteins utilizing... Agent:

20120087937 - Novel compositions: This disclosure provides novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease. The constructs are chimeric proteins comprising L1 proteins with an HPV L2 peptide inserted in to the L1 protein. Such chimeric proteins may be formulated into immunogenic e.g., vaccine compositions, and optionally... Agent:

20120087936 - Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection: Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be... Agent: The Regents Of The University Of Colorado, A Body Corporate

20120087938 - Consensus/ancestral immunogens: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or... Agent: The Regents Of The University Of California

20120087939 - Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection: Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins,... Agent:

20120087940 - Vector for treating alzheimer's disease: The present invention provides methods for efficiently inducing anti-Aβ antibody and methods for preventing and treating Alzheimer's disease. The present inventors successfully induced anti-Aβ antibody in a highly efficient manner by administering an RNA viral vector that expresses a fusion protein between an AB5 toxin B subunit and an Aβ... Agent: Dnavec Corporation

20120087943 - Agent for preventing adverse side effects of carcinostatic agent: The present invention provides a side effect inhibitor of drug therapy for colorectal cancer using 5-fluorouracil, comprising fucoidan or a fucoidan-containing material; a method for inhibiting side effects of drug therapy for colorectal cancer using 5-fluorouracil, which comprises administering fucoidan or a fucoidan-containing material to a colorectal cancer patient; and... Agent:

20120087941 - Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin: Discloses is a topical skin care composition and method for its use comprising Codium tomentosum extract and Crithmum maritimum extract or algae extract, wherein the composition is formulated as an emulsion, cream, lotion, solution, gel, ointment, or anhydrous base.... Agent: Mary Kay Inc.

20120087942 - Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin: Disclosed is a topical skin care composition and method for its use comprising water, Chlorella vulgaris extract, an algae extract, a phospholipid or lecithin, glycerin, retinyl palmitate, tocopheryl acetate, and magnesium ascorbyl phosphate.... Agent: Mary Kay Inc.

20120087944 - Oral vaccine fast-dissolving dosage form using starch: A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, wherein an immune response is induced in a patient in need thereof.... Agent: R.p. Scherer Technologies, LLC

20120087945 - Method for keeping an immunogenic composition available for administration to an animal: The present invention pertains to a method for keeping an immunogenic composition available for administration to an animal, wherein said composition comprises an antigen and an emulsion which is a single emulsion at a first temperature below a body temperature of the animal and which emulsion reverses at a second... Agent:

20120087946 - Recombinant bacterium and methods of antigen and nucleic acid delivery: The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response.... Agent: The Arizona Board Of Regents For And On Behalf Of Arizona State University

20120087947 - Use of 2,5-dihydroxybenzene derivatives for treating dermatitis: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.... Agent: Amderma Pharmaceuticals, LLC

20120087951 - Fabric with antimicrobial properties: A method of producing a fabric with antimicrobial properties that includes liquefying bamboo to produce a slurry, adding an antimicrobial element to the slurry, adding a non-bamboo fiber to the slurry to create a mixture and extruding the mixture to produce a fiber. The antimicrobial fabric may include a composition... Agent:

20120087950 - Functionalized calcium phosphate artificial bone and joint compositions and methods of use and manufacture: The present invention provides a functionalized composition and resulting functionalized body or prosthesis for in vitro and in vivo use comprising at least one calcium phosphate containing phase that is functionalized with a linker group comprising at least one of an organic acid molecule, a phosphonic acid, an amine, N,N-dicyclohexylcarbodiimide,... Agent:

20120087954 - Ion substituted calcium phosphate coatings: A method for the formation of a surface coating of an ion substituted calcium phosphate on a substrate, the coating itself and the use of the coating.... Agent: Biomatcell Ab

20120087956 - Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries: A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to... Agent:

20120087958 - Multi-dimensional biomaterial and method for producing the same: Biomaterial having a multi-dimensional structure and comprising differentiated MSCs tissue and demineralised bone matrix, wherein said demineralised bone matrix is dispersed within the differentiated MSCs tissue, method for producing the same and use thereof.... Agent: Universite Catholique De Louvain

20120087959 - Nanodispersion of a drug and process for its preparation: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more drugs, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol... Agent: Sun Pharma Advanced Research Company Limited

20120087955 - Nanoparticulate megestrol formulations: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Pharma International, Limited

20120087949 - Oligonucleotide micelles: The present invention provides homogenous populations of micelles, methods for preparing these populations, methods for treating or preventing a disease or disorder using the population of micelles of the invention.... Agent: University Of Florida Research Foundation, Inc.

20120087948 - Particulate cartilage system: The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions.... Agent: Isto Technologies, Inc.

20120087953 - Pharmaceutical compositions of active pharmaceutical ingredient comprising sulphonylurea moiety with excellent dissolution properties: The present invention provides a pharmaceutical composition comprising at least one active pharmaceutical ingredient comprising sulphonylurea moiety, wherein the at least one active pharmaceutical ingredient comprising sulphonylurea moiety is intimately mixed with a basic agent. The weight ratio of the basic agent and the at least one active pharmaceutical ingredient... Agent: Lek Pharmaceuticals D.d.

20120087957 - Process for the preparation of pharmaceutical suspensions for inhalation: Process for preparing sterile suspensions for inhalation comprising an active ingredient insoluble in water and wherein at least 80% of the particles of said active ingredient have a diameter between 3 and 5 μm, comprising the following stages: dissolving the active ingredient in the minimum quantity of an alcoholic solvent,... Agent: Chiesi Farmaceutical S.p.a.

20120087952 - Pulmonary delivery in treating disorders of the central nervous system: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about... Agent: Civitas Therapeutics, Inc.

20120087960 - Cation compatible metal oxides and oral care compositions containing the metal oxides: A cationic compatible metal oxide and oral care compositions containing the metal oxide are disclosed. Preferably, the oral care compositions contain a cationic compatable metal oxide and a cationic ingredient, such as for example, a cationic antibacterial agent such as cetyl pyridinium chloride (“CPC”). The cationic compatible metal oxide, e.g.... Agent:

20120087961 - Hepatitis a virucide: The invention relates to agents which combat the hepatitus A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production.... Agent: Ecolab Usa Inc.

20120087962 - Novel article: Aspects of the present invention are directed to personal protection articles, such as protective clothing, articles for sequential contact with multiple users, and cellulosic articles, which have their surface a coating formulation having activity to de-activate pathogenic micro-organisms, the coating comprising an acidic polymer, suitably the polymaleic acid material Gantrez™,... Agent:

20120087963 - Disinfectant composition comprising a biguanide compound: Disclosed is a method for killing spores from a surface or a material, comprising applying an effective amount of a biocidal composition which comprises one or more biguanide polymers, and one or more further active agents on said surface or material, characterised in that the or each further active agent... Agent: Bio Technics Limited

20120087964 - Highly wettable, water dispersible, granules including two pesticides: The present disclosure relates to water dispersible granular pesticide compositions, and methods of making and using the compositions. The pesticide compositions include an inner layer including a first pesticide coated on to a substrate, and an outer layer comprising a second pesticide coated on the inner layer. The outer layer... Agent: Ecolab Usa Inc.

20120087965 - Antimicrobial and antiodor solutions and delivery systems: A buffering system is also preferable in the solution, and the solution may be provided directly as a liquid, as a spray, as a gel, imbibed and carried in a wipe, encapsulated solution, segregated droplets of solution (in carrying layers of particles, dispersed in a solid of gel carrier) and... Agent: Biolargo Life Technologies, Inc.

20120087966 - Antimicrobial foam: A resilient foam material having an active antimicrobial bound to, incorporated within, and projecting from its surface is provided for incapacitating or destroying microbes. The antimicrobial has an atomic structure that is capable of mechanically piercing or lysing a microbe thereby incapacitating or destroying the microbe. The resilient antimicrobial foam... Agent: Obe Goods, LLC

20120087967 - Disinfectant and sanitizer for cosmetics and cosmetic tools: Disclosed is a disinfecting, sanitizing, and conditioning product which may be applied to cosmetics and cosmetic tools.... Agent:

20120087968 - Antimicrobial packaging material and methods of making and using the same: The presently disclosed subject matter is generally directed to packaging materials comprising at least one antimicrobial agent. Particularly, the disclosed packaging materials incorporate, via extrusion into the sealant layer, an antimicrobial agent based on the lauroyl arginate (LAE) moiety. Such packaging materials are suitable for use in the packaging of... Agent: Cryovac, Inc.

20120087969 - Mu-conotoxin peptides and use thereof as a local anesthetic: In one embodiment, the present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. An embodiment of the invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.... Agent: Atheris Laboratories

20120087970 - Apparatus and method for removing epithelium from the cornea: An apparatus and a method for removing epithelium from the cornea include a fluid agent for facilitating de-epithelialization of the cornea. A disc includes a biocompatible material operable for covering a predetermined zone of a cornea. The disc is hydrated by the fluid agent, wherein the hydrated disc is pliable... Agent:

20120087971 - Contact drug delivery system: A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having... Agent: Auburn University

20120087972 - Winnie wipes: After urinating; the Winnie Wipes would be used to remove urine from the end/tip of a Male's penis. Then, the male using his “free hand” too remove a 1 ply flexible thin plastic “back” sided wipe, from the container/dispenser; grasping the plastic “pull” “tab”. Then, dabbing/pressing the “front” napkin\tissue side;... Agent:

20120087976 - Adjuvant compositions comprising a non-ionic isotonicity agent: The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.... Agent:

20120087974 - Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages: The present invention provides compositions comprising allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages. In some embodiments a positive charge and enhancers are used in the compositions to allow for increased penetration of the active ingredient through skin and skin appendages. In some... Agent:

20120087975 - Method of producing a cationic liposomal preparation comprising a lipophilic compound: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.... Agent: Medigene Ag

20120087973 - Sirna microbicides for preventing and treating diseases: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1... Agent: Immune Disease Institute, Inc.

20120087977 - Aqueous carbonated medium containing an amino(meth)acrylate polymer or copolymer: The invention relates to an aqueous medium containing an amino(meth)acrylate polymer or copolymer which is not soluble in demineralised water, characterized in that the medium has a content of an aqueous phase of at least 60% by weight and a content of up to 40% by weight of solids comprising... Agent: Evonik Roehm Gmbh

20120087978 - Dosage forms of apixaban: The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form.... Agent: Pfizer Inc.

20120087979 - Extended-release oral dosage forms for poorly soluble amine drugs: Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the... Agent: Abon Pharmaceuticals, LLC

20120087980 - Stimulation of neuroregeneration by flavonoid glycosides: Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.... Agent:

20120087982 - Extended release opioid abuse deterrent compositions and methods of making same: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.... Agent: Acura Pharmaceuticals, Inc.

20120087981 - Skin engaging member comprising encapsulated actives: A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising an encapsulated active contained in a matrix material, an encapsulated active comprising at least one nano-particle encapsulated in a micro-particle, wherein said nano-particle comprises a shell comprising a hydrophobic material, and wherein said... Agent:

20120087983 - Orthopedic application of encapsulated stem cells: Described herein are orthopedic applications of mesenchymal stem cell encapsulated and delivered for treatment of cartilage damage in joints. A therapeutic composition is prepared comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in microbeads of a three-dimensional biocompatible gel matrix. The hydrogel microbeads encapsulating stem cells maintain the... Agent: Jointechlabs, Inc.

20120087984 - Stabilization of chemical compounds using nanoparticulate formulations: Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or... Agent: Elan Pharma International Ltd.

20120087985 - Small peptide sequences for stabilizing biomolecules: Disclosed herein are a class of small molecules, referred to as Small Peptide Sequences (SPS), that can stabilize biomolecules, particles containing the SPS and biomolecules, and compositions and methods of making the particles. The SPS are composed solely of amino acids common to humans and too small to trigger an... Agent: Biodel Inc.

20120087986 - Pharmaceutical formulations comprising desvenlafaxine: Pharmaceutical formulations comprising desvenlafaxine, processes for preparing formulations comprising desvenlafaxine, and therapeutic uses and methods of treatment employing formulations comprising desvenlafaxine.... Agent:

20120087987 - Combined use of two insecticides: The present disclosure relates to the combined use of two pesticides. A first pesticide composition provides an initial contact kill, and may form a barrier when applied to greasy surfaces. A second pesticide composition provides residual pesticidal activity on the surface. Methods of making and using the pesticide compositions are... Agent: Ecolab Usa Inc.

20120087988 - Methods and compositions for treating respiratory conditions using platelet enriched plasma: Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in... Agent:

20120087989 - Use of gelled prp (platelet gel) for volumetric breast reconstruction: The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants.... Agent: Universitat Aut&#xd2 Noma De Barcelona

20120087990 - Method for producing active hydrogen-dissolved water and apparatus for producing the same: e

20120087991 - Mucositis prevention supplement and treatment: The present invention provides for a nutritional composition comprising from 0.25 g to 25 g of glutamine, in neutral or salt form or precursor or derivative thereof; and from 0.1 g to 10 g of a phytochemical or a mixture thereof, wherein the phytochemical is an antioxidant. The nutritional composition... Agent: Fresenius Kabi Deutschland Gmbh

20120087992 - Mirnas as therapeutic targets in cancer: Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53)... Agent:

20120087993 - Biocidal aldehyde composition for oil and gas extraction: A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide (preferably TTPC), alcohol (preferably isopropyl alcohol), and functional excipients for the oil and gas recovery industry. The functional excipients for the oil and gas recovery industry are a cellulose type proppant, a poloxamer wetting agent, a friction-reducing pluronic block copolymer, a... Agent:

20120087994 - Systemic administration of nac as an adjunct in the treatment of bioterror exposures such as smallpox and use in combination with dhea for the treatment of smallpox: The invention is for the combination and related methods of N-acetyl-cysteine oral, inhaled, or intravenous, or glutathione inhaled or intravenous, generally in combination with antibiotic and/or antiviral therapy to ameliorate the toxic effects of infection with materials used in Bioterror incidents such as Bacillus anthracis and smallpox virus, and alternatively,... Agent:

20120087995 - Nfat signal inhibitor and calcineurin inhibitor: e

20120087996 - Antioxidant skin care compositions: Antioxidant skin care composition comprising at least two antioxidant components one of which is a solid coffee extract antioxidant, which exhibits a synergistically increased antioxidant potency as measured by ORACsc compared to the antioxidant potency of antioxidant skin care compositions which do not contain at least two antioxidant components one... Agent:

20120087997 - Edible products with thermostatic and cognitive effects: An edible product for normalizing blood sugar levels is provided. The product includes a mulberry extract having a (w/w) flavonoids concentration of at least 10%, a 1-deoxynojirimycin (DNJ) concentration of about 2% and a GABA concentration of about 1% of the total amino acid content of said mulberry extract.... Agent: Innosense Ltd.

20120087998 - Treatment of inflammatory bowel disease: The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the Musa spp. The soluble fibre may in particular be derived from plantains... Agent: Provexis (ibd) Limited

20120082616 - Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject.... Agent: Mallinckrodt LLC

20120082617 - Immunoconjugates with an intracellularly-cleavable linkage: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.... Agent: Immunomedics, Inc.

20120082618 - Prostate cancer diagnosis and treatment: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting,... Agent: Proscan Rx Pharma Inc.

20120082619 - Labelled adrenomedullin derivatives and their use for imaging and therapy: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is... Agent:

20120082620 - Methods and compositions for treatment of add/adhd, depression, memory problems and other conditions: Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions.... Agent:

20120082621 - Swallowtail motifs for imparting water solubility to porphyrinic compounds: wherein: Z is a porphyrinic macrocycle, Alk1 and Alk2 are each independently an alkylidene chain; L is a linking group or is absent; R1 is preferably an ionic group or polar group; R2 is an ionic group, polar group, bioconjugatable group, or targeting group; R3 is present or absent and... Agent:

20120082622 - Macaca fascicularis ccl17: Isolated polynucleotides encoding Macaca fascicularis CCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.... Agent:

20120082623 - Shh regulation and methods thereof: The invention provides for methods of upregulating endogenous GDNF by inhibiting Shh signaling. The invention further provides a method for increasing the production of cholinergic neurons and dopamine neurons by subventricular zone (SVZ) neurogenesis in a subject. The invention further provides methods for treating a neurodegenerative disorder in a subject.... Agent:

20120082624 - Method for preparing a pharmaceutical formulation of lanthanide chelate in powder form: e

20120082625 - Combination treatment for rosacea: The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema... Agent:

20120082627 - Otic foam formulations: The present invention relates to foamable otic pharmaceutical compositions comprising fluoroquinolones and methods of preparing same. Particularly, the present invention relates to pharmaceutical compositions comprising oil-in-water emulsions comprising fluoroquinolones and gas propellants, administered to the ear as foam for treating ear disorders.... Agent: Otic Pharma Ltd.

20120082626 - Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders: The present invention concerns with a new use of R-Bambuterol or Bambuterol as inhaled medicament for treatment of asthma, COPD and other respiratory disorders, and a new use of R-bambuterol or bambuterol and corticosteroids or other therapeutically active medicament as combined inhaled therapies. The invention also related to a new... Agent:

20120082628 - Oral care compositions with improved flavor: Oral care compositions having improved taste, said compositions comprising: a carrier material; from about 0.001 to about 10%, by weight of the composition, of an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof; and from about 0.0001 to... Agent:

20120082629 - Associative thickeners for aqueous preparations: Described are associative thickeners based on compounds which comprise at least one hydrophobically modified polyether dendron end group.... Agent: Basf Se

20120082630 - Oral care compositions with improved sweetness: The present invention is directed to improved sweetener compositions and oral care compositions, especially those in the form of a toothpaste or oral/dental rinse, comprising the same. The sweetener composition comprises a combination of saccharin, sucralose and a rebaudioside, or sweeteners of similar sucrose equivalence and type, preferably in a... Agent:

20120082631 - Compositions: An oral care composition comprising at least one polyvalent metal ion salt and at least one of maltol (M), ethyl maltol (E), and cyclotene (C) such that the concentration (in ppm by weight of the total oral care composition) of maltol (M), ethyl maltol (E), and cyclotene (C) meet the... Agent:

20120082632 - Topical drug delivery system with dual carriers: a solvent suitable for solubilizing a non-liquid active ingredient into a solution; a diluent for diluting the solvent to optimize the solution for mammalian tissue compatibility; and a stabilizer for maintaining the solution chemically stable and substantially free from oxidation during storage for a pre-determined shelf life period.... Agent:

20120082633 - Hair cosmetic: The present invention provides a hair cosmetic composition contains (A) a di-long-chain cationic surfactant represented by formula (1); (B) an ethylene oxide adduct of 1,2-alkanediol represented by formula (2) and/or an N-acyl-N-methylmonoethanolamide represented by formula (3); and (C) a hydrophobicized alkyl cellulose represented by formula (4) and/or a cationic polymer... Agent: Shiseido Company, Ltd.

20120082634 - Treatment for dyslipidemia: The present invention relates to compounds, and compositions, useful for treating dyslipidemia.... Agent: Solvotrin Therapeutics Ltd.

20120082635 - 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors: The present invention is related to novel 2-Amino-2-[8-(dimethyl carbamoyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-exo-ethanoyl derivatives of the general formula (A), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or... Agent: Lupin Limited

20120082636 - Stabilized alpha helical peptides and uses thereof: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive... Agent:

20120082637 - Lacquer composition comprising a monomer with a polyalicyclic structure element: A transparent lacquer composition that can be used as a protective and gloss lacquer for surface coating is described. The lacquer composition can be a dental material and a method for preparing a lacquer composition is also described. Also described are novel polymerizable monomers comprising at least one polyalicyclic structure... Agent: Voco Gmbh

20120082638 - Water-soluble and biodegradable antimicrobial agent: t

20120082639 - Compositions for attracting blood-feeding insects: Methods and compositions suitable for influencing insect behaviour are provided. In a preferred embodiment, the compositions comprise a blend of between two and eight insect attractant compounds selected from the group consisting of: a) compounds of formula (I); b) compounds of formula (II); c) compounds of formula (III). Wherein: n... Agent:

20120082641 - Formulations for bovine granulocyte colony stimulating factor and variants thereof: This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.... Agent: Eli Lilly And Company

20120082642 - Reversal of adult onset disorders with granulocyte-colony stimulating factors: A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors.... Agent:

20120082640 - Small molecule apoptosis promoters: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and... Agent:

20120082645 - 2'-c-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions, and uses thereof: The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl cytidine prodrugs and pharmaceutical compositions thereof to treat viral diseases such as hepatitis C.... Agent: Xenoport, Inc.

20120082643 - Compositions and methods for modulating a cytotoxic t lymphocyte immune response: The present invention provides compositions and methods for the treatment and prevention of immune disorders.... Agent: Dana-farber Cancer Institute, Inc.

20120082644 - Cytokines and neuroantigens for treatment of immune disorders: The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided.... Agent:

20120082646 - Antiviral compounds and uses thereof: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts,... Agent: Abbott Laboratories

20120082647 - Interferon-beta for use as monotherapy or in combination with other cancer therapies: This description relates to the use of a polymer-conjugated interferon-beta as monotherapy or in combination with other cancer therapies.... Agent:

20120082648 - Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria: Escherichia coli strains, such as enterotoxigenic E. coli strains, genetically engineered to express from recombinant plasmids one or more colonization factors (CFs) associated with enterotoxigenic Escherichia coli bacteria (ETEC) in an increased amount compared to said CFs expressed by ETEC wild-type reference strains, as well as a method of producing... Agent:

20120082650 - Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain: A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease. The protocol is practiced by directly delivering a definite concentration of a nerve growth factor via delivery of the protein,... Agent: Ceregene, Inc.

20120082651 - Bacteria thya(-) mutants with increased vitamin k: Bacteria thyA(−) mutants with increased vitamin K and use of these thyA(−) mutants for making a composition/product for treatment and/or prevention of vitamin K deficiency in a mammal (e.g. a human).... Agent:

20120082649 - Perivascular mesenchymal precursor cells: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC... Agent: Angioblast Systems, Inc.

20120082652 - Methods and devices for collecting separate components of whole blood: A method provides for procuring platelet rich plasma (PRP) from a sample of whole blood in a vial. The method includes the steps of: separating the whole blood into layers through centrifugation with an upper layer containing platelet poor plasma (PPP) and a PRP layer below the upper layer containing... Agent: Depuy Miltek, Inc.

20120082653 - Methods of lysosomal storage disease therapy: Methods of treating a lysosomal storage disorder and methods of increasing cellular uptake of a lysosomal enzyme using β2 agonists or therapeutic agents that increase expression of receptors for a lysosomal enzyme.... Agent: Duke University

20120082654 - Method for preventing and controlling organisms that infest aqueous systems: Method for preventing and controlling organisms that infest aqueous systems in which one or more organic or inorganic compounds capable of releasing gas are present, comprising the step of dispersing on and/or in the aqueous mass a preparation comprising enzymes adapted to catalyze a reaction of the one or more... Agent:

20120082655 - Downregulation of spy1 by p53 as an essential component of p53-mediated effects: The present invention relates to a novel method of treating or preventing cancer as well as a novel method for diagnosing or monitoring cancer, wherein the cancer is caused by delayed entry to cellular senescence. More particularly, the present invention relates to a novel method of treating or preventing cancer,... Agent:

20120082656 - Composition comprising the purified extract of bee venom for preventing and treating degenerative brain disease: The present invention relates to a composition comprising the purified extract of bee venom for preventing and treating degenerative brain diseases and the use thereby. The purified extract of bee venom shows potent inhibitory effect on microglial cell activation and abnormal circling behavior using by animal model of degenerative brain... Agent:

20120082657 - Skin preparation containing fermented soybean paste: The present invention relates to a skin preparation containing fermented soybean paste, which has been traditionally called as ‘Chungkookjang’ in Korea. Further, the skin preparation of present invention has a useful effect for preventing or treating the atopic dermatitis by the active ingredients contained in Chungkookjang. Further, the skin preparation... Agent:

20120082660 - Anti-tnf induced apoptosis (atia) diagnostic markers and therapies: The invention features diagnostic and therapeutic methods and compositions featuring Anti-TNF Induced Apoptosis (ATIA). ATIA is useful as a diagnostic marker for cancer, in particular for glioblastoma. ATIA is also a therapeutic target in diseases such as cancer. The invention encompasses combination therapies where knockdown of ATIA is used in... Agent: Govt. Of The United States Of America Dept. Of Health & Human Services

20120082659 - Methods and compositions related to synergistic responses to oncogenic mutations: Disclosed are compositions and methods related to new targets for cancer treatment.... Agent:

20120082658 - Methods for the treatment of allergic diseases: The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis.... Agent: Ventirx Pharmaceuticals, Inc.

20120082661 - Anti-bcma antibodies: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune... Agent:

20120082662 - Anti-cmet antagonists: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20120082663 - Anti-cmet antagonists: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20120082667 - Antibodies that specifically bind to a beta oligomers and use thereof: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.... Agent: Immunas Pharma, Inc.

20120082666 - Antibody compositions and methods of use: The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same.... Agent:

20120082664 - Optimized antibodies that target cd19: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Agent:

20120082665 - Prevention and treatment of pain using antibodies to sphingosine-1-phosphate: The present invention relates to use of anti-S1P agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain.... Agent:

20120082669 - Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors,... Agent:

20120082668 - Soluble il-17ra/rc fusion proteins and related methods: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F.... Agent: Zymogenetics, Inc.

20120082672 - Botulinum neurotoxin b receptors and use thereof: It is disclosed here that synaptotagmin I (syt I) and synaptotagmin II (syt II) are the cellular receptors for botulinum neurotoxin B (BoNT/B) that mediate the cellular entry and toxicity of BoNT/B. The BoNT/B binding domains of syt I and II are also disclosed. While syt I needs gangliosides for... Agent:

20120082670 - Cd33 binding agents: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).... Agent: Boehringer Ingelheim International Gmbh

20120082674 - Enterococcus antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.... Agent: Intercell Ag

20120082673 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Zymogenetics, Inc.

20120082671 - Modulation of activity of neurotrophins: Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one... Agent: H. Lundbeck A/s

20120082675 - Insulin-like growth factor signaling and integrin: Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially integrin alpha v beta 3, alpha 6 beta. 1 and alpha 6. beta. 4. A method for inhibiting integrin signaling by using an inhibitor of IGFI-integrin... Agent: The Regents Of The University Of California

20120082676 - Methods for preventing and treating angioedema: One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides... Agent: The Research Foundation Of State University Of New York

20120082677 - Compositions for the treatment of hcv and hbv: Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of hepatitis C infected patients.... Agent:

20120082679 - Antagonists of pcsk9: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors,... Agent: Merck Sharp & Dohme Corp.

20120082680 - Antagonists of pcsk9: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors,... Agent: Merck Sharp & Dohme Corp.

20120082681 - Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders: The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFNγ production of blood cells and compositions... Agent: Novartis Ag

20120082678 - Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a... Agent: Celera Corporation

20120082682 - Il-13 binding protein: The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF.... Agent:

20120082683 - Superagonistic anti-cd28 antibodies: e

20120082684 - Diagnosis and treatment of cell proliferation and differentiation disorders based on the fmn2 gene: The present invention provides methods for diagnosing cell proliferation and/or differentiation disorders, compounds and methods for treating the same and methods for identifying agents potentially useful in the treatment of cell proliferation and/or differentiation disorders.... Agent: University Court Of The University Of Dundee

20120082685 - Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy: The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41,... Agent: Ibc Pharmaceuticals, Inc.

20120082686 - Neovascular-targeted immunoconjugates: Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to... Agent: Yale University

20120082690 - Chaperonin 10 immunosuppression: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly... Agent: Cbio Limited

20120082688 - In vitro generation of myeloid derived suppressor cells: The invention relates to methods of isolating, culturing, and differentiating myeloid derived suppressor cells (MD-SCs) from embryonic stem (ES) cells and hematopoietic stem cells (HSCs). In certain embodiments, the invention relates to methods and compositions for producing MDSCs from ES cells and HSCs using a combination of factors including macrophage... Agent: Mount Sinai School Of Medicine

20120082689 - Method of treatment an oncological disease: Method of cancer treatment with direct contact between proteins secreted by cancer tumor and patient's blood T-lymphocytes including the stage of weakening during some time humoral system of immunity by medical preparation, in particular by immunodepressant against this system, without weakening cellular system of immunity.... Agent:

20120082687 - Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (aim) from the peripheral blood and methods of use: Disclosed is a method to recover an antigen presenting cells (APCs) and immune cells rich mixture (AIM) from peripheral blood mononuclear cells (PBMC) mobilized with one or more cell adhesion inhibitors for the preparation of an AIM vaccine or an AIM adoptive immunotherapy preparation. In addition, AIM mobilization can be... Agent:

20120082691 - Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.... Agent: Immatics Biotechnologies Gmbh

20120082692 - Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy: The present invention pertains to methods for identifying a HLA-A*2402-restricted cryptic epitope in an antigen, and for increasing its immunogenicity, in order to obtain HLA-A*2402-restricted epitopes able to trigger an immune response against HLA-A*2402-restricted cryptic epitopes. Isolated peptides consisting of cryptic or optimized HLA-A*2402-restricted epitopes are provided.... Agent: Vaxon Biotech

20120082693 - Use of proteins and peptides encoded by the genome of a novel sars-associated coronavirus strain: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents... Agent: Institut Pasteur, Centre National De La Recherche Scientifique, And Universite Paris

20120082694 - Recombinant viral-based malaria vaccines: Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses... Agent: Crucell Holland B.v.

20120082695 - Cosmetic active preparation: A cosmetic formulation comprises extracts and/or their derivatives, i.e., sea aster, brown algae, coral algae and Irish moss. In addition, metal-bound peptides are also contained in the cosmetic formulation. These components of the cosmetic formulation reinforce each other mutually so that the entire formulation exhibits favorable moisturizing effects that soothe... Agent: Axel Ruth

20120082696 - Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva): The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA... Agent:

20120082697 - Method for prophylaxis of influenza using vaccine for intranasal administration: The present invention provides a vaccine composition for transnasal mucous membrane administration, which contains an influenza virus antigen, polyriboinosinic polyribocytidylic acid (poly (I:C)) or a derivative thereof and a carboxyvinyl polymer. The present invention also provides a prophylactic method of influenza, including a step of administering the vaccine composition at... Agent: The Research Foundaton For Microbial Diseases Of Osaka University

20120082698 - Mutants of francisella tularensis and uses thereof: The present invention relates to a mutant Francisella tularensis strain comprising an inactivated clpB gene and compositions comprising such mutant. Methods of producing the mutant are also described. The present invention also encompasses a method of conferring immunity against F. tularensis in a host, comprising administering the described mutant F.... Agent:

20120082699 - Method of producing rough strains of bacteria and uses thereof: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4′-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof.... Agent: Bioeos Limited

20120082700 - Compositions for stimulation of mammalian innate immune resistance to pathogens: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a TLR9 agonist and a TLR 2/6 agonist to the individual.... Agent:

20120082702 - Nicotinamide compounds useful as kinase modulators: Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds.... Agent: Bristol-meyers Squibb Company

20120082703 - Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals: s

20120082701 - Polarized scorpion venom solution and a method for making polarized scorpion venom solution: The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation,... Agent:

20120082706 - Medical device for drug delivery: A medical device for safe and sure delivery of drugs to the lesion and a method for production thereof. The medical device has at least part of its surface in contact with the lumen wall tissue of the living body coated with a drug releasing layer containing a drug and... Agent: Terumo Kabushiki Kaisha

20120082704 - Oxygenated demineralized bone matrix for use in bone growth: An improved composition for inducing bone growth is provided that is a combination of at least DBM and an oxygen carrier. Injection/implantation of a composition of DBM and an oxygen carrier (e.g. a perfluorocarbon) results in enhancement of bone formation compared to DBM alone.... Agent:

20120082705 - Tetra calcium phosphate based organophosphorus compositions and methods: Compositions and methods of their use to adhere a variety of materials together are disclosed herein. The compositions include at least tetra calcium phosphate, an effective amount of a compound that is structurally similar to phosphoserine, and can be mixed with an aqueous solution. The compositions provide adhesive and cohesive... Agent: Howmedica Osteonics Corp.

20120082707 - Antiperspirant products having antibacterial protection and processes for making the same: A personal care product comprises an antiperspirant product that comprises an active antiperspirant compound, and titanium dioxide particles that comprise anhydrous silver compound selected from the group consisting of anhydrous silver chloride, anhydrous silver lactate, anhydrous silver citrate, and mixtures thereof.... Agent: The Dial Corporation

20120082709 - Compositions and methods for delivery of materials: Compositions for delivering release materials, for example drugs, agricultural materials, other bioactive materials, cosmetic materials, organic or inorganic compounds which take part in or catalyse a chemical reaction, a fragrance-emitting material for a vaporizer, or a lubricating material. The release material is associated with a crystalline carrier. The carrier may... Agent: Landec Corporation

20120082708 - Novel method for preparing composite particle comprising surface treatment layer of sunscreening agent formed thereon: The present invention relates to a method of preparing a composite powder comprising a surface treatment layer of sunscreen. The present invention prepares a composite powder comprising a surface treatment layer of sunscreen by a dry process that does not require separate dehydration and drying processes, and thus, the prepared... Agent: Sunjin Chemical Co., Ltd.

20120082710 - Methods and compositions for treating acne: A method for treating acne on the skin. The method has the steps of (a) providing an drapeable or flexible porous article impregnated with an aqueous cleansing composition having a carrier, benzoyl peroxide, and one or more cleansing agents; (b) contacting an area of the skin affected by acne with... Agent: Medicis Pharmaceutical Corporation

20120082711 - Antimicrobial compositions and fibres incorporating the same: The present application defines an antimicrobial composition comprising (a) at least two antimicrobial agents having different antimicrobial mechanisms of action and being present in amounts that together provide a synergistic antimicrobial effect or (b) an antimicrobial agent and a surface modifying agent, an antimicrobial masterbatch comprising antimicrobial composition (a) or... Agent:

20120082712 - Implantable polymeric films: The present disclosure relates to implantable medical devices containing a polymeric film layer containing glycerol and at least one biopolymer.... Agent:

20120082713 - Photochrome- or near ir dye-coupled polymeric matrices for medical articles: The invention provides polymers comprising pendent photochrome or near IR dye groups, as well as polymeric matrices made from these polymers, which can be used as or in association with a medical article. The polymers can be synthesized using methods that facilitate the preparation of medical articles having good biocompatibility.... Agent:

20120082714 - Transdermal therapeutic system with crystallization-inhibiting protective film (release liner): The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.... Agent: Bayer Pharma Aktiengesellschaft

20120082715 - Stabilized products, processes and devices for preparing the same: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of... Agent:

20120082717 - Complex, multilayer using the same, and device coated with the multilayer: Disclosed herein is a complex, wherein micelles and/or liposomes dispersed in hyaluronic acids and/or hyaluronic acid derivatives, with a drug and/or functional material loaded in the micelles and/or the liposomes. The complex can release the drug and/or functional material in a controlled manner. Also, a multilayer using the complex, and... Agent: Iljin Materials Co., Ltd.

20120082716 - Cytotoxic agents: A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterised in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′... Agent: Btg International Limited

20120082718 - Morphine formulations: Described is a pellet composition comprising a core element comprising morphine sulfate, a filler and a binder, wherein the morphine sulfate, calculated as the anhydrous form, comprises about 50 wt % to about 85 wt % of the total weight of the core element; and a coating disposed on at... Agent: Alpharma Pharmaceuticals, LLC

20120082719 - Compositions for treating chronic viral infections: The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections.... Agent:

20120082720 - Compositions for treating chronic viral infections: The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections.... Agent:

20120082721 - Enteric coating: The present invention refers to a dosage form comprising an enteric coating in a specific amount, and to the use of enteric coating compositions for preparing a dosage form. Furthermore, the present invention also relates to a process for the preparation of a solid oral dosage form.... Agent: H E X A L Aktiengesellschaft

20120082722 - Methods and compositions for oral delivery of fts: Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists.... Agent: Concordia Pharmaceuticals, Inc.

20120082723 - Easily administrable solid preparation: It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected... Agent: Mochida Pharmaceutical Co., Ltd.

20120082724 - Dry mouldable drug formulation: Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.... Agent: Novo Nordisk A/s

20120082725 - Composition comprising immunogenic microparticles: The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.... Agent: Px Biosolutions Pty Ltd

20120082726 - Surface-treated modafinil particles: The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof.... Agent: Cephalon, Inc.

20120082727 - Use of magnesium stearate in dry powder formulations for inhalation: Addition of magnesium stearate to a powder formulation for inhalation comprising carrier particles and an active ingredient bearing a group susceptible to hydrolysis is useful for inhibiting or reducing the chemical degradation of the active ingredient.... Agent: Chiesi Farmaceutici S.p.a.

20120082728 - Multifunctional stealth nanoparticules for biomedical use: The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional... Agent: Universite De Strasbourg

20120082729 - Quick dissolve compositions and tablets based thereon: The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred... Agent: Valeant International (barbados) Srl

20120082732 - Medicine for treatment of a carcinoma: In a method for treating a carcinoma in a patient, a medicine is administered via the blood stream of the patient that appears, to the patient's immune system, that tissue of the carcinoma is an inflammation source. The medicine employs two active components that are coupled to each other in... Agent:

20120082731 - Method for removing residual organic solvent from microparticles: Disclosed herein are methods comprising suspending microparticles in a surfactant/non-polar alkane solution to remove residual solvent that is present in the microparticle.... Agent:

20120082730 - Nanoparticulate in-situ gels as vitreous humor substitutes for ocular diseases: The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation... Agent: Indian Institute Of Technology Bombay

20120082733 - Methods for processing microspheres, microspheres processed thereby, and uses thereof: The invention provides a manufacturing method for processing polymeric microspheres which are suspended in a liquid. The invention also provides polymeric microspheres produced by the method which can be used in medical settings as tissue fillers, tissue bulking agents, embolization agents, and/or as drug delivery agents.... Agent:

20120082734 - Hydrogen production device, hydrogen addition device and hydrogen-additive article: A hydrogen production device includes a reaction unit and a hydrogen collection unit. The reaction unit includes a first region, a second region and a barrier layer. The first region stores a solid-state reactant, the second region stores a liquid-state reactant, and the barrier layer separates the first region from... Agent:

20120082735 - Allergic skin desease topical cream: Disclosed is a cream formulation containing calamine, an H1 antihistamine, and a corticosteroid for the reduction of inflammation, redness and itching associated with acute and chronic allergic skin disease.... Agent:

20120082736 - Small-molecule tnf modulator to reduce the side effects of chemotherapy and radiotherapy: Cancer patients treated by chemotherapy and/or radiotherapy often suffer serious side effects. Currently, there is only one FDA approved and used as both a chemoprotector and a radioprotector, amifostine, which is associated with significant problems. Disclosed in the present invention are novel methods of using UTL-5g as both a chemoprotector... Agent: 21st Century Therapeutics, Inc.

20120082737 - Topical skin care formulations comprising plant extracts: Disclosed are compositions and corresponding methods of their use that include extracts from a Lonicera maackii and Polygonum hydropiper. The composition can be used to reduce tyrosinase activity and elastase activity in skin cells.... Agent: Mary Kay Inc.

20120082738 - Mucosal formulation: Provided, among other things, is a method of treating or ameliorating an indication of mucosal or adjacent tissue comprising periodically applying to mucosa at or adjacent to disease affected tissue a rinse comprising: an effective amount of appropriate composition of herbal bioactive comprising active(s) of one or more of Sambucus... Agent: Izun Pharmaceuticals Corporation

20120082739 - Compositions and methods for treatment and management of pain: Disclosed herein are compositions and methods for the treatment and management of pain in a subject, comprising topically or orally administering a therapeutically effective amount of a composition comprising herbal extracts and compound mixtures to a subject. The composition includes turmeric extract, Boswellia extract, ginger extract, holy basil extract, rosemary... Agent:

20120082740 - Method for increasing concentration of avenanthramides in oats: Methods for increasing the levels of avenanthramides in oats through false malting is disclosed. Oats are first subject to induction or enhancement of a secondary dormancy, and then malted for up to 5 days at an elevated temperature. The malted but not germinated oats are then dried and used as... Agent: Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture

20120082741 - Compositions and methods for the prevention and treatment of red blood cell coagulation: A pharmaceutical composition for inhibiting mammalian red blood cell coagulation is disclosed. The composition comprises an effective amount of Geum japonicum's organic extract and a pharmaceutically acceptable carrier.... Agent: Generex Pharmaceuticals, Inc.

20120082742 - Method and compositions for treating cutaneous verrucae: By incorporating certain pharmaceutical and cosmetic preservative agents into nail polish vehicles containing corrosive ingredients, the risk and prevalence of recurrence of verrucae can be substantially reduced.... Agent: Elorac, Ltd